third
intern
symposium
respiratori
viral
infect
conven
macra
group
new
york
ny
st
lucia
windward
island
decemb
third
time
symposium
provid
forum
virologist
vaccinologist
clinician
pharmacologist
public
health
specialist
discuss
recent
advanc
respiratori
viru
research
interdisciplinari
fashion
kaiser
et
al
munoz
et
al
spectrum
discuss
rang
basic
virolog
pathogenesi
vaccinolog
immunolog
manag
strategi
respiratori
viral
infect
epidemiolog
respiratori
viral
diseas
possibl
prepar
next
influenza
pandem
also
import
part
agenda
influenza
virus
known
filter
human
respiratori
tract
pathogen
shope
recov
influenza
viru
swine
probabl
first
human
influenza
viru
isol
two
year
later
smith
andrew
laidlaw
recov
first
influenza
isol
human
soon
effort
develop
inactiv
influenza
vaccin
began
influenza
b
c
isol
franci
taylor
respect
laboratori
infecti
diseas
lid
nation
institut
health
hilleman
work
walter
reed
armi
medic
center
recov
first
human
adenovirus
establish
import
acut
febril
respiratori
tract
diseas
row
et
al
hilleman
follow
year
robert
chanock
discov
remain
respiratori
virus
consid
import
lower
respiratori
tract
pathogen
today
first
croupassoci
myxoviru
discov
outbreak
croup
cincinatti
later
design
human
parainfluenza
viru
type
morri
colleagu
recov
chimpanze
coryza
agent
cca
outbreak
coldlik
ill
chimpanze
coloni
year
later
chanock
colleagu
recov
two
similar
isol
infant
bronchopneumonia
anoth
infant
laryngotracheobronch
character
human
viru
known
respiratori
syncyti
viru
rsv
chanock
et
al
discoveri
singl
common
caus
croup
second
common
caus
seriou
viral
pediatr
lower
respiratori
tract
diseas
respect
broaden
understand
etiolog
acut
lower
respiratori
tract
diseas
chanock
et
al
discoveri
follow
short
order
doubleblind
prospect
studi
evalu
use
tetracyclin
treatment
cold
agglutininposit
atyp
pneumonia
led
identif
etiolog
agent
diseas
agent
origin
recov
eaton
patient
form
pneumonia
known
filter
thought
viru
role
etiolog
agent
heavili
disput
larg
doubleblind
studi
chanock
kingston
mufson
antibodi
eaton
viru
use
defin
subset
patient
pneumonia
show
tetracyclin
therapi
decreas
durat
diseas
therebi
exclud
viru
etiolog
subsequ
eaton
agent
shown
chanock
hayflick
baril
mycoplasma
grew
cellfre
medium
later
name
mycoplasma
pneumonia
chanock
et
al
serolog
analys
studi
adult
volunt
confirm
etiolog
role
organ
cold
agglutininposit
atyp
pneumonia
renew
effort
vaccin
develop
respiratori
virus
began
observ
infant
young
children
recov
respiratori
tract
infect
adenovirus
shed
viru
gastrointestin
tract
extend
period
time
without
experienc
gastrointestin
symptom
led
hypothesi
one
could
potenti
use
gastrointestin
tract
vaccin
respiratori
tract
diseas
caus
virus
wildtyp
adenoviru
type
administ
oral
entericco
capsul
found
protect
militari
recruit
respiratori
tract
diseas
caus
virus
gastrointestin
symptom
observ
although
viru
shed
intestin
infect
close
contact
couch
et
al
develop
vaccin
respiratori
virus
suffer
major
setback
formalininactiv
rsv
vaccin
fail
protect
infant
rsv
infect
instead
potenti
rsv
diseas
upon
subsequ
rsv
infect
kim
et
al
inactiv
vaccin
induc
potent
neutral
antibodi
respons
stimul
exagger
cell
respons
without
stimul
cytotox
cell
unanticip
failur
nonliv
vaccin
reorient
research
agenda
laboratori
infecti
diseas
toward
develop
liveattenu
viru
vaccin
coldpassag
rsv
strain
select
first
candid
liveattenu
rsv
vaccin
strain
friedewald
et
al
candid
vaccin
safe
immunogen
adult
older
children
insuffici
attenu
seroneg
infant
kim
et
al
sinc
search
live
rsv
vaccin
strain
central
focu
lid
develop
live
rsv
vaccin
candid
attenu
yet
immunogen
seroneg
infant
prove
formid
task
sinc
incid
morbid
rsv
highest
second
third
month
life
vaccin
candid
safe
administr
neonat
abl
stimul
immatur
immun
system
abl
overcom
immunosuppress
antivir
effect
passiv
acquir
matern
rsv
antibodi
initi
vaccin
candid
deriv
late
earli
passag
viru
low
temperatur
cold
passag
chemic
mutagenesi
sever
differ
lineag
mutant
temperatur
sensit
mutant
gener
mutagenesi
evalu
infant
young
children
insuffici
attenu
genet
unstabl
coldpassag
cp
mutant
subsequ
attenu
acquisit
two
missens
mutat
confer
temperatur
sensit
ts
yield
cpt
rsv
provid
promis
vaccin
candid
test
thu
far
candid
vaccin
viru
infecti
safe
immunogen
seroneg
infant
confer
protect
challeng
second
dose
vaccin
viru
week
later
caus
mild
upper
respiratori
tract
symptom
wright
et
al
recent
develop
method
rescu
infecti
rsv
cdna
collin
enhanc
abil
develop
rsv
vaccin
candid
rapidli
collin
et
al
sitedirect
mutagenesi
use
first
time
construct
virus
one
addit
attenu
mutat
use
recombin
cdna
technolog
viabl
rsv
mutant
delet
sh
gene
construct
vaccin
candid
bear
genet
stabl
attenu
mutat
reason
like
liveattenu
vaccin
exhibit
accept
balanc
attenu
immunogen
develop
within
next
sever
year
vaccin
viru
might
possess
one
gene
delet
mutat
togeth
without
earlier
character
coldpassag
cp
temperaturesensit
ts
mutat
first
piv
vaccin
candid
also
prepar
formalininactiv
similar
experi
formalininactiv
rsv
vaccin
protect
piv
diseas
earli
belsh
attenu
isol
passag
belsh
hissom
clinic
studi
vaccin
candid
prove
safe
genet
stabl
immunogen
seroneg
infant
karron
et
al
vaccin
candid
current
test
phase
ii
clinic
trial
recombin
version
rescu
cdna
genet
basi
attenu
att
temperaturesensit
ts
coldadapt
ca
phenotyp
determin
skiadopoulo
et
al
influenza
b
viru
vaccin
develop
follow
path
serial
passag
coldadapt
gener
mutant
att
ts
ca
phenotyp
maassab
maassab
bryant
contrast
piv
rsv
live
attenu
influenza
vaccin
strain
viru
reassort
gener
mate
attenu
donor
viru
epidem
wild
type
viru
reassort
viru
vaccin
chimera
contain
attenu
gene
donor
viru
ha
na
gene
deriv
current
epidem
viru
murphi
et
al
strategi
develop
john
maassab
use
coldadapt
mutant
viru
donor
six
attenu
intern
nonstructur
gene
construct
reassort
vaccin
strain
valid
larg
seri
consecut
reassort
proven
attenu
immunogen
analysi
genet
basi
attenu
show
influenza
gene
consist
specifi
ts
phenotyp
pa
specifi
ca
phenotyp
howev
three
gene
viral
polymeras
complex
contribut
attenu
trival
influenza
b
vaccin
virus
murphi
maassab
bryant
safeti
protect
efficaci
phenotyp
stabil
confirm
larg
phase
iii
trial
licensur
expect
near
futur
belsh
et
al
evid
prophylact
effect
serum
rsv
neutral
antibodi
demonstr
princ
et
al
passiv
transfer
homolog
rsv
convalesc
serum
cotton
rat
protect
rsv
replic
lung
follow
subsequ
intranas
challeng
wild
type
viru
serum
rsv
neutral
titer
recipi
cotton
rat
confer
almost
complet
protect
amount
neutral
antibodi
necessari
protect
later
confirm
clinic
trial
today
form
basi
passiv
rsv
prophylaxi
highrisk
infant
groothui
et
al
increas
incid
sever
rsv
diseas
seen
preterm
infant
without
chronic
lung
diseas
cld
children
congenit
heart
diseas
chd
immunosuppress
children
adult
respiratori
diseas
gener
common
caus
rehospit
preterm
infant
cunningham
colleagu
compar
cohort
preterm
infant
mean
gestat
age
birth
week
cohort
term
infant
found
increas
readmiss
respiratori
diseas
preterm
infant
without
cld
increas
preterm
infant
cld
respect
cunningham
et
al
cld
patient
home
oxygen
program
even
higher
risk
hospit
icu
admiss
groothui
et
al
children
pulmonari
disord
cystic
fibrosi
lung
malform
recurr
aspir
pneumon
admit
rsv
diseas
like
requir
icu
treatment
mechan
ventil
children
cld
respect
arnold
et
al
earlier
studi
highrisk
infant
admit
rsv
diseas
yield
similar
result
icu
treatment
necessari
mechan
ventil
necessari
meert
et
al
nava
et
al
apart
preterm
infant
without
cld
children
congenit
heart
diseas
chd
second
group
highrisk
patient
particularli
suffer
pulmonari
hypertens
prospect
studi
children
hospit
five
consecut
rsv
season
patient
rsv
diseas
chd
compar
patient
without
chd
requir
icu
treatment
die
macdonald
et
al
prospect
studi
children
chd
incid
rsvrelat
hospit
one
rsv
season
children
younger
year
infant
younger
month
age
simo
et
al
immunocompromis
children
divers
popul
equal
risk
sever
rsv
infect
children
receiv
corticosteroid
therapi
much
lower
risk
rsvrelat
hospit
death
children
receiv
chemotherapi
malign
children
primari
immunodefici
rsvrelat
mortal
chemotherapyrecipi
children
primari
immunodefici
compar
steroidtr
children
hall
et
al
rsv
grew
high
titer
children
receiv
chemotherapi
half
patient
shed
rsv
week
longer
immunocompromis
adult
pictur
much
differ
describ
children
infect
often
acquir
nosocomi
viru
shed
prolong
incid
pneumonia
death
high
rsv
import
viral
respiratori
pathogen
patient
follow
picornavirus
influenza
parainfluenza
virus
confirm
rsv
infect
leukemia
bone
marrow
transplant
patient
result
pneumonia
fatal
rate
greater
whimbey
colleagu
report
rsv
case
fatal
rate
bone
marrow
transplant
recipi
high
therapi
administ
earli
adequ
ribavirin
ivig
therapi
initi
late
inadequ
hivinfect
children
urban
set
south
africa
also
increas
burden
viral
lower
respiratori
tract
ill
lri
although
respiratori
virus
less
frequent
isol
nasopharyng
aspir
hivinfect
children
children
without
hiv
infect
rel
risk
sever
lri
caus
rsv
twice
high
hivinfect
uninfect
children
two
year
age
younger
madhi
et
al
littl
inform
avail
regard
genet
environment
factor
suscept
rsv
infect
rsv
epidemiolog
studi
conduct
affluent
countri
temper
climat
although
rsv
thought
lead
caus
sever
viral
acut
respiratori
infect
ari
infant
around
globe
weber
et
al
prospect
surveil
studi
conduct
yukonkuskokwim
yk
delta
southwestern
alaska
determin
rate
sever
rsv
infect
requir
hospit
infant
yupik
eskimo
popul
karron
et
al
annual
rate
rsv
hospit
yk
delta
infant
less
year
age
unusu
high
ie
one
children
born
yk
delta
compar
one
one
infant
affluent
countri
sim
et
al
martin
et
al
glezen
et
al
requir
ventilatori
support
rsv
diseas
rsv
infect
singl
frequent
caus
hospit
yk
delta
infant
temper
climat
rsv
epidem
yk
delta
occur
annual
novemb
june
peak
hospit
rsv
diseas
occur
novemb
februari
within
subregion
yk
delta
epidem
brief
month
probabl
limit
traffic
villag
winter
month
infant
admit
hospit
less
year
age
medic
risk
factor
rsv
diseas
surprisingli
admit
infant
yk
delta
infant
comparison
group
admit
john
hopkin
hospit
jhh
less
one
month
old
children
sever
diseas
yk
delta
jhh
less
month
old
diseas
sever
nonhigh
risk
children
differ
children
admit
jhh
yk
delta
region
hospit
suggest
differ
hospit
practic
could
account
high
rate
hospit
rsv
yk
delta
infant
yk
delta
admit
rsv
diseas
readmit
within
singl
rsv
season
sever
rsv
diseas
age
first
ill
receipt
ribavirin
associ
readmiss
infant
less
month
age
low
neutral
antibodi
titer
cord
blood
sampl
strongli
associ
sever
diseas
questionnairebas
case
control
studi
match
age
subregion
yk
delta
detect
three
risk
factor
influenc
rsv
hospit
admiss
medic
risk
factor
prematur
chronic
lung
diseas
congenit
heart
diseas
increas
risk
admiss
eight
peopl
live
one
household
doubl
risk
hospit
breastfeed
protect
effect
smoke
foodpr
chew
econom
statu
significantli
associ
rsv
hospit
studi
may
use
continu
analysi
impact
rsv
develop
countri
yk
delta
rsv
lead
caus
viral
lower
respiratori
tract
diseas
develop
countri
lack
access
diagnost
reagent
hospit
facil
made
difficult
quantifi
impact
rsv
also
rate
sever
rsv
diseas
term
neonat
much
higher
earlier
studi
yk
delta
popul
comparison
group
baltimor
find
confirm
popul
import
implic
rsv
vaccin
develop
respiratori
syncyti
rsv
human
hrv
infect
children
aid
lower
respiratori
tract
ill
lrti
acut
respiratori
infect
ari
caus
great
burden
diseas
develop
countri
de
arruda
et
al
although
grow
number
children
develop
nation
hiv
infect
littl
knowledg
frequenc
sever
viral
ari
hiv
infect
children
earlier
studi
viral
pathogen
immunocompromis
adult
indic
cmv
herp
simplex
influenza
parainfluenza
rhinoviru
adenoviru
enteroviru
rsv
caus
lower
respiratori
infect
connolli
et
al
recent
studi
assess
frequenc
rsv
rhinovirus
hrv
hospit
children
without
aid
present
lower
respiratori
tract
infect
lrti
episod
lrti
children
aid
children
without
hiv
infect
match
age
sampl
collect
month
studi
rural
area
southern
brazil
frequenc
rsv
infect
highest
fall
winter
februari
juli
wherea
hrv
detect
throughout
year
rsv
found
lrti
episod
aid
nonhiv
infect
children
respect
hrv
found
episod
children
aid
hivuninfect
children
respect
differ
detect
frequenc
hrv
rsv
infect
two
group
hrv
infect
howev
tend
frequent
associ
pneumonia
children
aid
control
group
p
clinic
present
lrti
observ
equal
frequenc
find
confirm
hrv
caus
agent
pneumonia
children
aid
suggest
studi
lrti
desir
intervent
hrv
could
consid
immunocompromis
children
lrti
human
adenovirus
ad
larg
famili
serotyp
well
numer
variant
intermedi
divid
six
subgroup
af
exhibit
differ
tissu
tropism
clinic
manifest
adenovir
diseas
protean
common
respiratori
syndrom
children
adult
estim
ad
caus
respiratori
diseas
children
includ
pharyng
tonsil
pertussislik
syndrom
children
adult
ad
also
associ
lower
respiratori
tract
infect
bronchiti
pneumonia
subgroup
ad
associ
epidem
sporad
ocular
infect
includ
conjunct
keratoconjunct
due
stabil
environ
virus
highli
transmiss
particularli
nosocomi
set
adult
ad
caus
largescal
epidem
acut
respiratori
diseas
ard
close
popul
militari
recruit
dormitori
resid
longterm
care
facil
occup
primarili
associ
ad
serotyp
lesser
extent
serotyp
replic
gastrointestin
tract
featur
ad
infect
subgroup
f
associ
gastroenter
infant
young
children
ad
infect
immunocompromis
subject
increas
number
increas
sever
consequ
clinic
manifest
ad
infect
immunocompromis
patient
includ
pneumonia
hepat
enceph
system
dissemin
diseas
case
fatal
rate
depend
natur
immunodefici
nearli
ad
serotyp
associ
infect
higher
number
subgroup
serotyp
usual
associ
clinic
diseas
immunocompet
host
especi
common
number
new
diseas
associ
ad
infect
recent
report
probabl
due
improv
highli
sensit
molecular
diagnost
techniqu
also
increas
probabl
laboratori
contamin
detect
viral
genom
absenc
posit
viral
cultur
describ
case
myocard
pericard
children
adult
martin
et
al
bowl
et
al
pausching
et
al
sudden
infant
death
shimizu
et
al
toxic
shocklik
syndrom
price
unexplain
death
perkin
et
al
isol
ad
patient
central
nervou
system
manifest
fatal
acut
flaccid
paralysi
cardosa
et
al
enceph
cerebr
edema
chatterje
et
al
also
report
perhap
surpris
clinic
manifest
ad
infect
evolv
virus
process
continu
evolut
ad
mutat
repertoir
includ
homolog
recombin
illegitim
recombin
singl
base
mutat
sbm
homolog
recombin
occur
conserv
region
genom
close
relat
virus
within
subgroup
requir
region
homolog
two
parent
strand
primari
mechan
respons
intermedi
ad
mosaic
virus
share
hexon
characterist
hexon
characterist
one
type
fiber
anoth
illegitim
recombin
requir
short
region
homolog
one
three
nucleotid
short
direct
repeat
thought
result
polymeras
stutter
slippag
caus
delet
insert
duplic
short
region
dna
ad
occur
noncod
region
hypervari
region
hvr
hexon
capsid
protein
toler
structur
variat
hvr
hexon
contain
viral
neutral
epitop
mutat
region
result
delet
format
alter
epitop
lead
antigen
shift
primari
mechan
new
serotyp
aris
particularli
among
fastest
grow
group
subgroup
ad
singl
base
mutat
accumul
gradual
across
viral
genom
occur
higher
rate
hvr
caus
increment
antigen
drift
creation
variant
strain
ad
evolut
compound
three
mechan
perhap
other
yet
defin
result
serolog
identif
subgroup
ad
becom
extrem
difficult
seem
reason
time
come
consid
sequencebas
ad
classif
system
similar
use
papillomavirus
enterovirus
adenoviru
reemerg
lead
caus
febril
respiratori
diseas
among
militari
recruit
larg
frequent
epidem
common
traine
camp
elimin
introduct
live
enter
type
vaccin
sole
vaccin
manufactur
discontinu
product
live
enter
coat
vaccin
contractu
issu
limit
vaccin
store
still
avail
vaccin
store
complet
deplet
earli
monitor
effect
discontinu
vaccin
weekli
surveil
febril
respiratori
infect
fri
defin
oral
temperatur
respiratori
diseas
symptom
conduct
octob
four
militari
train
camp
interv
throat
cultur
yield
adenoviru
winter
adenoviru
infect
caus
fri
four
camp
ad
account
isol
respect
three
train
camp
experienc
high
preval
adenoviru
type
fourth
camp
experienc
type
outbreak
among
symptomat
traine
receiv
vaccin
time
like
infect
ad
vaccin
subject
gray
et
al
surveil
extend
eight
site
june
viru
isol
attempt
adenoviru
influenza
b
rsv
parainfluenza
larg
ad
epidem
observ
six
train
camp
throughout
us
rsv
influenza
b
virus
isol
less
frequent
impact
adenoviru
epidem
basic
train
hardli
overestim
recruit
camp
forc
convert
barrack
special
infirmari
care
ill
hospit
forc
halt
elect
surgeri
one
camp
number
traine
repeat
basic
train
extend
ill
increas
recycl
extrem
neg
effect
moral
traine
impact
militari
readi
mani
prevent
adenovir
traine
medic
encount
occur
winter
month
two
militari
traine
die
molecular
evid
acut
adenovir
infect
one
encephalomyel
anoth
acut
respiratori
distress
syndrom
ard
vaccin
ad
proven
extrem
safe
effect
prevent
enorm
burden
diseas
militari
traine
howel
et
al
urgent
new
manufactur
adenovir
vaccin
identifi
vaccin
product
must
resum
soon
possibl
recent
year
much
progress
made
understand
virusinduc
modul
host
immun
respons
viral
infect
ad
viral
gene
product
known
particip
modul
immun
respons
mani
gene
product
express
gene
cluster
earli
region
wold
et
al
horwitz
overal
effect
ad
gene
product
immun
respons
vivo
appreci
result
three
studi
mice
investig
transplant
reject
develop
autoimmun
diseas
first
studi
express
complet
ad
cassett
pancreat
islet
cell
transgen
control
rat
insulin
promot
rip
enabl
allogen
islet
donor
cell
contain
bxd
class
mhc
accept
longterm
recipi
mice
efrat
et
al
indic
ad
gene
product
could
potenti
use
power
tool
control
transplant
reject
second
studi
use
lymphocyt
choriomening
viru
lcmv
model
autoimmun
diabet
mellitu
lcmv
protein
np
gp
express
surfac
islet
cell
diabet
induc
infect
lcmv
induc
gp
np
tcell
mediat
immun
respons
model
coexpress
lcmvnp
gp
complet
prevent
onset
diabet
lcmv
infect
von
herrath
et
al
similar
protect
effect
ad
transgen
seen
third
studi
use
nonobes
diabet
mice
nod
model
diabet
mellitu
underli
mechan
current
investig
efrat
et
al
thu
understand
mechan
action
ad
immunoregulatori
gene
pursu
variou
system
util
control
select
immun
reaction
might
involv
genesi
autoimmun
diabet
bettercharacter
gene
product
region
order
increas
distanc
promot
function
shall
discuss
ad
gene
product
review
elsewher
horwitz
vitro
reduc
express
class
major
histocompat
complex
mhc
molecul
retain
mhc
heavi
chain
endoplasm
reticulum
retriev
back
golgi
also
inhibit
peptid
process
bennett
et
al
cotton
rat
model
adenoviru
pneumonia
delet
mutant
replic
like
wildtyp
viru
induc
much
stronger
inflammatori
respons
ginsberg
et
al
wherea
mice
increas
pulmonari
patholog
seen
sparer
et
al
ad
protein
inhibit
tnfainduc
cell
death
process
involv
downregul
tnfareceptor
cotton
rat
ginsberg
et
al
mice
sparer
et
al
delet
ad
modifi
pulmonari
inflammatori
respons
ie
increas
polymorphonuclear
leukocyt
cotton
rat
pronounc
alveolar
infiltr
mice
order
determin
ad
protein
prevent
cell
death
cell
protein
interact
viral
protein
determin
use
yeast
twohybrid
system
four
protein
fip
identifi
three
character
shown
particip
quit
divers
cellular
pathway
li
et
al
li
et
al
li
et
al
also
known
raga
rasrel
small
gtpase
bind
tctel
compon
microtubul
motor
protein
dynein
form
complex
lukashok
et
al
postul
affect
microtubul
depend
macromolecular
transport
even
modul
transport
viru
howev
structur
protein
adenovirus
must
made
de
novo
earli
viral
transcript
unlik
play
role
viral
entri
even
though
process
known
microtubul
depend
role
viral
exit
cell
studi
also
bind
second
gtpase
local
centrosom
addit
potenti
effect
mitosi
may
involv
transport
macromolecul
nucleu
cytoplasm
bind
abnorm
huntingtin
specif
expand
polyglutamin
tract
appear
associ
cell
death
neuron
huntington
diseas
faber
et
al
whether
ad
andor
prevent
huntingtininduc
cell
death
current
investig
overexpress
also
call
nfkb
essenti
modul
nemo
inhibitor
kappa
kinas
gamma
ikkg
caus
morpholog
chang
eventu
apoptosi
varieti
cell
line
amount
apoptosi
induc
reduc
ad
present
apart
seem
interact
number
key
molecul
tnf
receptor
nfkb
signal
pathway
receptor
interact
protein
rip
inhibitor
kappa
b
kinas
beta
ikkb
nfkb
induc
kinas
nik
li
et
al
exampl
effect
ad
gene
product
pathobiolog
diseas
differ
autoimmun
diabet
transplant
reject
huntington
diseas
indic
much
remain
learn
studi
adenovirushost
interact
rsv
strain
genom
singl
strand
negativesens
rna
nucleotid
transcrib
major
subgenom
mrna
three
eleven
encod
protein
transmembran
protein
g
protein
mediat
attach
cell
surfac
receptor
f
protein
mediat
viruscel
cellcel
fusion
function
sh
protein
unknown
structur
protein
protein
play
role
virion
assembl
n
p
l
protein
make
viral
polymeras
protein
function
transcript
antitermin
factor
protein
includ
two
nonstructur
speci
protein
encod
second
orf
mrna
use
revers
genet
system
rescu
infecti
rsv
cdna
five
gene
rsv
ablat
individu
case
combin
without
render
viru
nonviabl
jin
et
al
five
nonessenti
gene
sh
g
sinc
gene
confer
select
advantag
rsv
vitro
andor
vivo
describ
virul
factor
delet
lead
attenu
viru
delet
small
hydrophob
sh
transmembran
protein
yield
recombin
rsv
call
replic
vitro
well
wild
type
wt
rsv
induc
plaqu
cell
larger
wt
rsv
plaqu
reduct
synthesi
rna
protein
associ
delet
sh
chimpanze
howev
viru
slightli
attenu
whitehead
et
al
delet
gene
result
substanti
reduct
replic
efficaci
vitro
reduct
pronounc
cell
vero
cell
lack
interferon
b
gene
suggest
two
gene
act
antagonist
type
interferon
effect
delet
bovin
rsv
provid
direct
evid
cooper
antagon
ab
interferoninduc
antivir
respons
schlender
et
al
chimpanze
level
replic
reduc
greater
lower
respiratori
tract
upper
respiratori
tract
viru
attenu
viru
teng
et
al
delet
identifi
markedli
attenu
rsv
mutant
reveal
import
role
orf
replic
cycl
rsv
bermingham
collin
infect
wildtyp
rsv
transcript
appear
shut
approxim
h
post
infect
rna
replic
increas
concurr
contrast
appar
switch
transcript
rna
replic
observ
viru
impli
regulatori
protein
involv
shift
instead
transcript
continu
increas
rna
replic
remain
low
compar
wildtyp
rsv
overal
gene
express
increas
fold
synthesi
g
f
protein
also
increas
result
increas
syncytium
format
replic
viru
vitro
attenu
probabl
due
reduc
rna
replic
bermingham
collin
jin
et
al
chimpanze
comparison
four
rsv
gene
delet
mutant
mention
wt
rsv
incomplet
attenu
rsv
vaccin
candid
result
hierarchi
increasingli
attenu
viruseswt
rsv
b
dsh
b
b
b
b
final
rsv
gene
delet
mutant
evalu
chimpanze
absenc
major
protect
antigen
would
desir
vaccin
viru
replic
effici
wt
rsv
vero
cell
show
g
essenti
effici
viru
replic
howev
rsvdg
viru
highli
attenu
balbc
mice
indic
import
rsv
g
protein
vivo
evid
rank
rsv
revers
genet
abl
gener
mutant
exhibit
gradat
level
attenu
menu
virus
differ
level
attenu
crucial
identifi
rsv
vaccin
exhibit
desir
balanc
attenu
immunogen
seroneg
infant
sinc
clinic
data
indic
rsv
slightli
underattenu
target
popul
mutant
could
exactli
need
order
rsv
assembl
effici
process
viral
structur
protein
must
brought
togeth
coordin
fashion
peepl
lenard
compar
paramyxovirus
rsv
exhibit
sever
uniqu
featur
g
protein
found
genu
role
protein
play
rsv
assembl
much
less
well
understood
role
f
hn
protein
collin
et
al
comparison
multipl
human
bovin
ovin
rsv
strain
show
cytoplasm
domain
f
g
protein
well
conserv
amongst
human
rsv
strain
subtyp
conserv
degre
three
speci
analog
paramyxovirus
like
cytoplasm
domain
f
g
interact
process
virion
assembl
cellular
protein
involv
protein
traffick
polar
bud
process
well
viral
protein
rsv
g
protein
coloc
golgi
apparatu
rsvinfect
cell
also
cell
transfect
g
protein
indic
viral
protein
need
interact
perouli
et
al
gm
interact
seen
fulllength
g
protein
secret
form
g
lack
conserv
cytoplasm
domain
transmembran
domain
systemat
delet
substitut
mutagenesi
cytoplasm
domain
g
identifi
sequencespecif
six
amino
acid
motif
directli
interact
perouli
et
al
rsv
infect
protein
initi
detect
nucleu
later
infecti
cycl
found
inclus
within
cytoplasm
ghildyal
et
al
unpublish
n
p
protein
rsv
earlier
shown
necessari
suffici
inclus
form
rsv
l
protein
also
shown
present
inclus
garcia
et
al
investig
unabl
identifi
protein
inclus
garcia
et
al
use
confoc
immunofluoresc
microscopi
infect
cotransfect
cell
protein
shown
present
inclus
protein
local
inclus
unless
also
present
protein
coloc
confoc
microscopi
also
interact
protein
overlay
assay
ghildyal
et
al
unpublish
taken
togeth
data
suggest
singl
strand
negativesens
virus
peepl
lenard
rsv
protein
seem
play
crucial
role
rsv
assembl
bring
nucleocapsid
togeth
envelop
protein
bind
cytoplasm
domain
g
f
nucleocapsid
protein
n
p
togeth
via
interact
nucleocapsid
protein
might
complex
outlin
might
involv
addit
cellular
viral
protein
better
understand
rsv
assembl
domain
protein
interact
g
f
defin
influenza
virus
readili
develop
resist
older
antivir
amantadin
rimantadin
resist
neuraminidas
inhibitor
occur
much
less
frequent
nonetheless
resist
influenza
viru
mutant
isol
patient
treat
oseltamivir
treanor
et
al
one
resist
mutant
carri
arginin
lysin
mutat
posit
neuraminidas
protein
caus
reduct
substrat
bind
enzymat
activ
well
resist
oseltamivir
mckimmbreschkin
infect
influenza
virus
carri
mutat
earlier
found
markedli
reduc
mice
ferret
transmiss
influenza
clinic
isol
mutat
studi
ferret
comparison
transmiss
parent
wt
viru
isol
patient
donor
ferret
four
per
group
inocul
intranas
mutant
wt
viru
hous
three
contact
ferret
per
donor
ferret
four
donor
inocul
wt
viru
infect
transmit
viru
contact
wild
type
viru
replic
pfuml
nasal
aspir
two
four
donor
ferret
inocul
mutant
viru
becam
infect
level
replic
mutant
viru
reduc
compar
wt
viru
howev
infect
ferret
transmit
viru
contact
one
transmit
viru
one
three
contact
viru
detect
low
titer
day
donor
transmit
viru
three
contact
transmit
viru
replic
titer
greater
pfuml
contact
ferret
sequenc
analysi
show
donor
viru
mix
popul
mutant
wt
viru
wt
viru
recov
contact
data
confirm
reduc
infect
oseltamivir
resist
mutant
effect
transmiss
mutant
viru
ferret
observ
suggest
transmiss
oseltamivirresist
viru
human
human
unlik
even
widespread
use
na
inhibitor
treatment
influenza
respiratori
viru
infect
immunocompromis
patient
character
persist
viral
infect
prolong
shed
viru
high
rate
nosocomi
acquisit
high
frequenc
pneumonia
death
similarli
respiratori
viru
infect
elderli
respons
substanti
amount
morbid
mortal
detect
respiratori
viru
infect
highrisk
patient
import
sever
reason
enabl
initi
specif
isol
procedur
initi
specif
antivir
therapi
cessat
unnecessari
therapi
test
procedur
aid
identifi
prevent
potenti
outbreak
respiratori
viru
infect
diagnos
use
serolog
cultur
techniqu
well
newer
method
antigendetect
enzymelink
immunoassay
eia
immunofluoresc
ifa
enzymat
detect
chemic
reaction
amplif
part
viral
genom
pcr
serolog
use
acut
phase
ill
limit
use
immunocompromis
patient
elderli
receiv
blood
product
recoveri
viru
cell
cultur
still
seen
gold
standard
mani
import
obtain
good
specimen
ensur
cultur
fals
neg
often
overlook
good
clinic
specimen
critic
factor
ensur
correct
diagnosi
regardless
diagnost
method
use
although
perhap
import
cultur
use
nasal
wash
obtain
specimen
viru
isol
welltoler
cooper
adult
compar
nasal
swab
throat
swab
increas
sensit
cell
cultur
viru
detect
factor
critic
laboratori
success
use
appropri
transport
media
temperatur
transportincub
time
process
atmar
englund
particularli
import
case
rsv
infect
immunocompromis
elderli
patient
often
rel
low
viral
titer
pfuml
wherea
children
often
titer
greater
pfuml
nasal
wash
bronchoalveolar
lavag
fluid
englund
et
al
rsv
parainfluenza
influenza
viru
number
commerci
avail
rapid
detect
kit
multipl
simultan
rtpcr
detect
rsv
influenza
b
hexaplex
test
pediatr
sampl
yield
sensit
specif
compar
cultur
fan
et
al
h
process
time
separ
studi
pcr
respiratori
virus
adult
patient
hematolog
malign
found
sensit
cultur
van
kraaj
van
elden
influenza
sever
antigen
detect
kit
directigen
fluoia
quickvu
one
neuraminidas
zstatflu
assay
avail
detect
viru
sensit
rang
specif
rang
rapid
diagnosi
influenza
pediatr
patient
lead
decreas
frequenc
durat
antibiot
use
increas
frequenc
antivir
therapi
noyola
demmler
rapid
diagnosi
kit
detect
rsv
children
rang
sensit
specif
test
kit
perform
better
other
dominguez
et
al
immunocompromis
adult
howev
sensit
antigen
detect
kit
nasal
wash
throat
swab
sampl
endotrach
bronchoalveolar
sampl
increas
sensit
respect
englund
et
al
sever
studi
recent
year
highlight
import
upper
respiratori
tract
infect
exacerb
asthma
children
freymuth
colleagu
report
human
rhinoviru
hrv
rsv
frequent
pathogen
detect
patient
exacerb
asthma
note
pcr
increas
detect
rate
hrv
rsv
infect
respect
convent
assay
freymuth
et
al
studi
wheez
children
month
year
age
respiratori
virus
detect
rsv
infant
detect
subject
hrv
older
children
predomin
pathogen
strongli
associ
wheez
rake
et
al
communitybas
longitudin
studi
respiratori
virus
detect
episod
acut
ill
reduc
peak
expiratori
flow
episod
wheez
episod
upper
respiratori
symptom
cough
wheez
fall
peak
expiratori
flow
johnston
et
al
set
rtpcr
provid
fast
sensit
method
detect
rna
virus
real
time
quantit
pcr
assay
similar
convent
pcr
specif
speed
howev
realtim
pcr
also
quantifi
viral
load
quantiti
viru
respiratori
secret
asthma
exacerb
sometim
sensit
convent
pcr
real
time
taqman
quantit
pcr
allow
estim
input
viral
genom
copi
number
includ
fluoresc
report
one
end
quench
molecul
report
fluoresc
quencher
cleav
exonucleas
activ
taq
polymeras
permit
estim
quantiti
pcr
product
fluoresc
measur
continu
everi
seven
second
quantif
target
base
number
pcr
cycl
take
produc
detect
fluoresc
retrospect
studi
conduct
asthmat
children
year
old
compar
viral
load
quiescent
exacerb
period
asthma
use
taqman
technolog
nasal
aspir
collect
earlier
record
peak
flow
measur
clinic
score
avail
quiescent
period
defin
absenc
clinic
symptom
two
week
longer
real
time
quantit
pcr
detect
respiratori
virus
mostli
rhinovirus
children
asthma
exacerb
children
quiescenc
viral
load
higher
children
exacerb
asthma
quiescent
asthma
higher
viral
load
also
correl
sever
clinic
diseas
although
studi
show
real
time
quantit
pcr
sensit
nonnest
convent
pcr
also
allow
estim
viral
load
caveat
studi
retrospect
design
modal
immun
acut
viral
respiratori
infect
specif
nonspecif
humor
cell
mediat
fever
interferon
ifn
tumor
necrosi
factor
tnf
natur
killer
cell
activ
macrophag
nonspecif
modal
stimul
infect
capabl
mediat
antivir
effect
lung
collectin
spa
also
implic
control
viral
respiratori
infect
ghildyal
et
al
specif
modal
antibodi
serum
secret
lymphocyt
prolifer
respons
cytokin
releas
cytotox
lymphocyt
ctl
modal
particip
degre
contain
infect
promot
recoveri
either
via
inactiv
free
viru
elimin
infect
cell
thu
consider
redund
mechan
control
viru
infect
promot
recoveri
hand
protect
infect
primarili
convey
specif
antibodi
suffici
data
avail
conclud
serum
igg
neutral
antibodi
primari
mediat
resist
influenza
viru
infect
presum
infect
initi
lower
respiratori
tract
igg
antibodi
deriv
serum
domin
antibodi
isotyp
site
couch
kasel
contrast
iga
antibodi
primari
mediat
resist
rhinoviru
coronaviru
infect
evid
indic
infect
initi
nasopharynx
iga
domin
antibodi
isotyp
cate
et
al
sinc
primari
infect
influenza
viru
rsv
piv
induc
diseas
upper
lower
respiratori
tract
igg
iga
antibodi
correl
immun
infect
diseas
crow
although
adenovirus
also
caus
upper
lower
respiratori
diseas
serum
antibodi
shown
correl
immun
reinfect
homolog
rsv
piv
rhinoviru
coronaviru
occur
gener
confin
upper
respiratori
tract
presum
igg
antibodi
protect
quantiti
durabl
serum
lower
respiratori
secret
iga
antibodi
nasopharyng
secret
rsv
risk
infect
declin
subject
one
two
infect
respect
risk
lower
respiratori
diseas
group
declin
respect
glezen
et
al
rhinoviru
resist
reinfect
nasopharynx
correl
titer
iga
antibodi
secret
cate
et
al
rodent
model
viral
respiratori
diseas
provid
much
earli
data
immun
modal
confer
protect
crow
cell
effect
clearanc
influenza
viru
rsv
piv
mice
absenc
cell
type
lightman
et
al
cytotox
lymphocyt
ctl
mediat
immun
lysi
infect
cell
express
antivir
cytokin
cell
exhibit
limit
direct
antivir
activ
play
role
activ
b
cell
induc
antivir
cytokin
express
epstein
et
al
gener
consensu
ctl
contribut
significantli
resolut
primari
infect
influenza
rsv
piv
rodent
correl
antibodi
respons
protect
human
establish
decad
ago
cellular
immun
respons
studi
much
later
understand
develop
respons
infant
immunosenesc
elderli
still
incomplet
whether
ctl
human
convey
immun
respiratori
viru
infect
lower
respiratori
tract
whether
promot
clearanc
viru
upper
respiratori
tract
human
remain
elucid
howev
rsv
diseas
human
correl
observ
presenc
rsvspecif
ctl
year
absenc
sever
rsv
diseas
year
mbawuik
press
morev
level
influenzaspecif
ctl
correl
invers
quantiti
viru
nasal
secret
challeng
human
abil
ctl
function
site
demonstr
reduct
influenza
viru
titer
nasal
turbin
mice
adopt
immun
purifi
ctl
intranas
challeng
mcmichael
et
al
mbawuik
person
commun
knowledg
regard
viralbacteri
interact
respiratori
tract
goe
back
least
influenza
pandem
interact
describ
later
influenza
pandem
well
epidem
pandem
influenza
follow
regularli
increas
incid
bacteri
pneumonia
schwarzmann
et
al
cartwright
et
al
associ
rsv
haemophilu
influenza
bordetella
pertussi
neisseria
meningitidi
staphylococcu
aureu
infect
also
describ
patel
et
al
jiang
et
al
interact
viral
bacteri
diseas
fairli
complex
underli
mechan
begin
elucid
known
upregul
tnfa
increas
adher
uptak
pneumococci
cundel
et
al
sever
cellular
receptor
bacteri
adher
upregul
viral
infect
pneumonia
h
influenza
interact
paf
receptor
sword
et
al
n
meningitidi
interact
raza
et
al
interact
regul
level
cell
surfac
receptor
mous
influenza
model
instanc
sever
damag
desquam
respiratori
epithelium
enabl
access
pneumonia
basal
membran
therebi
increas
risk
invas
diseas
plotkowski
et
al
otiti
media
tradit
thought
pure
bacteri
infect
pneumonia
h
influenza
moraxella
catarrhali
main
pathogen
recent
studi
howev
indic
major
acut
otiti
media
aom
case
result
mix
bacteri
viral
infect
heikkinen
colleagu
report
increas
rsv
parainfluenza
viru
influenza
adenoviru
infect
children
otiti
media
heikkinen
et
al
respiratori
viral
infect
nasopharynx
thought
predispos
aom
virus
eg
rsv
frequent
found
middl
ear
aom
mechan
underli
respiratori
tract
infectionaom
sequenc
involv
eustachian
tube
obstruct
lead
neg
middl
ear
pressur
inspiss
bacteria
middl
ear
giebink
et
al
children
rsv
adenoviru
influenza
viru
infect
risk
develop
aom
within
week
onset
respiratori
tract
infect
henderson
et
al
coinfect
bacteria
virus
also
advers
influenc
outcom
aom
aom
respond
antibiot
therapi
within
h
like
involv
viral
infect
arola
et
al
effect
viral
coinfect
complic
evalu
clinic
efficaci
antibacteri
drug
treatment
aom
marchant
et
al
bacterialvir
coinfect
aom
also
delay
clearanc
bacteria
middl
ear
antibacteri
therapi
compar
diseas
attribut
bacteri
infect
alon
chonmaitre
et
al
unclear
whether
decreas
efficaci
antibiot
due
impair
host
respons
poor
neutrophil
function
due
poor
penetr
antibiot
middl
ear
recent
clinic
trial
heptaval
pneumococc
vaccin
efficaci
prevent
bacteremia
efficaci
prevent
aom
caus
serotyp
includ
vaccin
howev
frequenc
aom
caus
pneumococci
includ
vaccin
increas
replac
phenomenon
overal
effect
vaccin
reduc
eskola
et
al
contrast
pneumococc
vaccin
viral
vaccin
seem
effect
prevent
aom
belsh
colleagu
report
consider
efficaci
attenu
live
influenza
vaccin
prevent
aom
rsv
prophylaxi
rsv
antibodi
also
associ
mark
decreas
otiti
media
belsh
et
al
group
human
adenovirus
consist
known
serotyp
divid
six
subgroup
af
distinctli
differ
organ
tropism
although
factor
may
influenc
infect
replic
virus
high
affin
attach
virion
host
cell
receptor
repres
key
determin
tissu
tropism
exampl
distinctli
differ
organ
tropism
predomin
subgroup
adenovirus
ad
pneumonia
patient
primari
immunodefici
prefer
subgroup
b
virus
urinari
tract
patient
kidney
transplant
predomin
subgroup
c
virus
hepat
liver
transplant
patient
receptor
bind
mediat
ad
fiber
protein
homotrimer
molecul
compos
amino
termin
region
anchor
fiber
penton
base
capsid
protein
elong
central
shaft
domain
van
raaij
et
al
carboxytermin
receptor
bind
knob
high
resolut
structur
fiber
knob
bound
receptor
coxsackieadenoviru
receptor
car
recent
obtain
xray
diffract
bewley
et
al
amino
acid
residu
directli
involv
receptor
bind
defin
sever
adenovirus
mutagenesi
studi
roelvink
et
al
adenovirus
differ
remark
isoelectr
point
fiber
protein
knob
domain
eg
ph
versu
ph
suggest
fiber
protein
use
receptor
besid
car
heparin
sulfat
proteoglycan
dechecchi
et
al
sialic
acid
arnberg
et
al
mediat
adenoviru
attach
sinc
car
express
basolater
lumin
surfac
epithelium
car
probabl
use
target
adenovir
vector
therapi
cystic
fibrosi
import
role
charg
play
viruscel
interact
deduc
differenti
effect
remov
sialic
acid
cell
surfac
neuraminidas
treatment
adenoviru
attach
attach
affect
neuraminidas
treatment
attach
increas
attach
decreas
differ
ph
optima
may
well
determin
tissu
tropism
major
pathogen
adenovir
eye
infect
belong
subgroup
similar
knob
charg
chimer
fiber
protein
whether
evolv
natur
gener
mutagenesi
caus
signific
chang
adenoviru
pathogenesi
new
genotyp
appear
argentina
uruguay
chile
caus
sever
respiratori
tract
infect
children
analysi
fiber
protein
reveal
chimera
contain
sequenc
new
genotyp
also
emerg
japan
absent
year
caus
outbreak
respiratori
diseas
fiber
protein
howev
factor
determin
adenoviru
tropism
viru
uptak
thought
also
mediat
interact
penton
base
protein
integrin
adenovirus
also
differ
abil
induc
inflammatori
respons
ad
potent
induc
interleukin
hallmark
cytokin
viral
pneumonia
might
explain
caus
signific
respiratori
diseas
summari
conclud
neither
subgroup
classif
alon
fiber
protein
knob
charg
alon
determin
adenoviru
tissu
tropism
key
amino
acid
knob
well
certain
motif
penton
base
protein
possibl
adenoviru
protein
interact
viru
attach
intern
avian
influenza
virus
subtyp
found
transmit
directli
poultri
human
hong
kong
virus
highli
pathogen
chicken
also
caus
sever
clinic
symptom
human
lead
death
six
infect
individu
order
obtain
better
understand
pathogenesi
tropism
kinet
replic
virus
primat
cynomolgu
monkey
macaca
fasciculari
infect
highli
pathogen
ahong
isol
obtain
index
case
four
monkey
inocul
tcid
ml
inoculum
administ
intratrach
oral
tonsil
onto
conjunctiva
two
monkey
euthan
day
remain
two
day
post
infect
two
monkey
euthan
day
post
infect
develop
respiratori
distress
syndrom
high
respiratori
rate
fever
day
day
one
monkey
letharg
sever
ill
central
cyanosi
monkey
also
ill
develop
fever
viru
replic
titer
greater
tcid
per
g
lung
tissu
day
could
isol
day
macroscop
lung
patholog
domin
peribronchi
consolid
necrot
lesion
histopatholog
examin
tissu
collect
day
post
infect
reveal
extens
patholog
chang
respiratori
tract
characterist
viral
necrot
interstiti
pneumonia
although
rtpcr
influenza
viru
posit
respiratori
tract
spleen
heart
also
cerebrum
cerebellum
one
monkey
viru
could
demonstr
immunoperoxidas
stain
isol
respiratori
tract
respiratori
tract
seem
major
probabl
target
influenza
viru
although
cynomolog
monkey
use
earlier
model
influenza
diseas
rimmelzwaan
et
al
first
time
primat
model
virus
describ
influenza
clinic
symptom
observ
studi
correl
well
seen
human
diseas
caus
highli
virul
virus
sever
seen
virus
therefor
cynomolog
monkey
may
provid
use
model
studi
influenza
pathogenesi
develop
vaccin
oral
mitogen
protein
map
kinas
inhibitor
pulmonari
function
murin
influenza
pneumonia
model
influenza
infect
respons
signific
morbid
especi
highrisk
group
underli
cardiopulmonari
diseas
elderli
patholog
result
vigor
inflammatori
respons
respiratori
tract
damag
respiratori
epitheli
cell
cell
expos
inflammatori
cytokin
mitogen
activ
kinas
map
activ
lead
upregul
cytokin
tnfa
ono
han
recent
studi
examin
effect
highli
select
oral
bioavail
inhibitor
map
kinas
pulmonari
function
mice
infect
influenza
viru
mice
infect
intranas
influenza
treat
differ
time
point
post
infect
initi
treatment
day
postinfect
result
p
pb
improv
pulmonari
capac
respect
compar
placebotr
control
anim
effect
viru
clearanc
surviv
antivir
immun
observ
efficaci
reduc
pulmonari
resist
increas
blood
oxygen
similar
neuraminidas
inhibitor
oseltamivir
steroid
dexamethason
inhibitor
nimesulid
superior
nonspecif
nsaid
indomethacin
naproxen
ibuprofen
mice
ferret
reduc
airway
neutrophilia
treatment
welltoler
without
advers
effect
data
suggest
map
kinas
involv
influenzainduc
cell
signal
inhibit
enzym
might
reduc
sever
pulmonari
diseas
fortun
number
virus
caus
respiratori
diseas
sever
enough
requir
hospit
limit
children
younger
five
year
rsv
subgroup
b
virus
parainfluenza
virus
influenza
b
adenoviru
type
major
respiratori
pathogen
influenza
b
remain
due
antigen
drift
shift
import
agent
age
group
sever
diseas
commonli
occur
elderli
rsv
singl
import
caus
sever
respiratori
diseas
infanc
childhood
also
caus
signific
morbid
elderli
immunocompromis
individu
kim
chanock
brandt
parrott
first
quantifi
contribut
virus
sever
respiratori
tract
diseas
lead
hospit
infant
young
children
rsv
adenovirus
influenza
b
caus
respect
respiratori
diseas
lead
hospit
influenza
respons
era
era
brandt
et
al
parrott
et
al
kim
et
al
murphi
et
al
gener
principl
underli
vaccin
develop
virus
first
protect
antigen
viru
mediat
immun
reinfect
larg
known
gener
accept
neutral
antibodi
surfac
glycoprotein
g
f
rsv
hn
f
piv
ha
na
influenza
capsid
protein
hexon
fiber
protein
adenovirus
major
mediat
resist
reinfect
second
serum
mucos
antibodi
make
independ
contribut
immun
reinfect
wherea
serum
antibodi
need
mediat
immun
lower
respiratori
tract
mucos
antibodi
need
protect
upper
respiratori
tract
except
adenoviru
serum
antibodi
alon
prevent
uri
third
live
viru
vaccin
gener
immunogen
nonliv
viru
vaccin
immunolog
subject
identifi
live
vaccin
viru
safe
suffici
immunogen
prove
difficult
task
fourth
differ
age
group
might
need
differ
vaccin
infant
younger
four
month
age
make
less
antibodi
older
children
due
immunosuppress
matern
antibodi
immatur
immun
system
potent
immunogen
eg
live
viru
vaccin
success
popul
murphi
et
al
hand
live
viru
vaccin
suffici
attenu
use
infant
might
overattenu
elderli
gonzalez
et
al
fifth
virus
differ
abil
caus
diseas
presenc
matern
serum
antibodi
mucos
deliv
rsv
influenza
infecti
presenc
matern
antibodi
adenoviru
seem
restrict
replic
young
infant
matern
antibodi
five
principl
need
consid
determin
optim
vaccin
strategi
system
versu
mucos
vector
antigen
versu
live
attenu
viru
target
age
vaccin
vaccin
avail
influenza
vaccin
current
use
us
mostli
nonliv
subvirion
vaccin
made
egggrown
purifi
viru
disrupt
deterg
practic
purpos
relev
protein
vaccin
influenza
hemagglutinin
strain
includ
vaccin
annual
vaccin
select
public
health
servic
base
antigen
profil
current
circul
strain
subivirion
subunit
vaccin
plu
adjuv
also
develop
minutello
et
al
gluck
et
al
live
attenu
viru
vaccin
base
coldadapt
influenza
strain
influenza
b
strain
evalu
phase
iii
clinic
trial
soon
becom
avail
mucos
vaccin
administ
nasal
spray
maassab
bryant
date
rsv
vaccin
licens
two
nonliv
viru
vaccin
rsv
develop
one
purifi
f
protein
subunit
vaccin
consist
g
proteinspecif
peptid
conjug
albumenbind
site
streptococcu
g
protein
cano
et
al
purifi
f
subunit
vaccin
evalu
use
seroposit
popul
elderli
highrisk
older
children
gonzalez
et
al
use
f
subunit
vaccin
disadvantag
induc
potent
mucos
antibodi
respons
also
antigen
induc
serum
antibodi
respons
domin
nonneutr
antibodi
high
ratio
titer
f
proteinspecif
bind
antibodi
titer
neutral
antibodi
subgroup
b
live
rsv
vaccin
candid
develop
one
candid
vaccin
bear
multipl
attenu
mutat
evalu
month
old
infant
found
attenu
immunogen
retain
mild
reactogen
upper
respiratori
tract
wright
et
al
like
recombin
cdna
technolog
use
develop
improv
live
attenu
rsv
vaccin
near
futur
whitehead
et
al
exampl
subgroup
b
rsv
vaccin
candid
develop
substitut
g
f
glycoprotein
gene
rsv
b
correspond
gene
attenu
recombin
subgroup
viru
whitehead
et
al
therebi
rapidli
gener
live
attenu
subgroup
b
rsv
vaccin
candid
date
piv
vaccin
licens
subunit
vector
vaccin
candid
develop
test
anim
model
report
ongo
clinic
trial
two
liveattenu
vaccin
candid
bovin
coldadapt
evalu
clinic
trial
virus
found
safe
immunogen
seroneg
infant
karron
et
al
karron
et
al
recombin
version
two
virus
also
evalu
vaccin
vector
express
foreign
viral
glycoprotein
rsv
g
measl
ha
karron
et
al
durbin
et
al
schmidt
et
al
recombin
vaccin
candid
current
test
phase
ii
trial
seroneg
infant
adenovirus
live
viru
vaccin
serotyp
use
success
militari
recruit
vaccin
made
use
sitespecif
attenu
ie
wt
viru
capabl
induc
respiratori
diseas
administ
respiratori
tract
administ
oral
enter
coat
capsul
vaccin
viru
replic
gastrointestin
tract
spread
respiratori
tract
oral
vaccin
found
complet
attenu
highli
efficaci
induc
serum
antibodi
protect
upper
lower
respiratori
tract
couch
et
al
howel
et
al
similar
tetraval
vaccin
serotyp
evalu
use
young
pediatr
patient
sinc
four
virus
respons
adenovirusrel
respiratori
tract
diseas
popul
virolog
revers
genet
refer
abil
rescu
infecti
viru
cdna
revers
genet
system
develop
major
viral
respiratori
pathogen
ie
influenza
viru
paramyxovirus
adenovirus
recent
coronavirus
short
review
address
impact
revers
genet
vaccin
develop
select
member
paramyxovirida
rsv
gener
attenu
vaccin
virus
start
convent
biolog
method
first
wildtyp
rsv
passag
extens
low
temperatur
result
coldpassag
cp
rsv
demonstr
attenu
chimpanze
well
seroposit
adult
young
children
friedewald
et
al
cprsv
viru
modifi
two
round
chemic
mutagenesi
biolog
select
temperaturesensit
crow
et
al
panel
result
mutant
virus
evalu
mice
chimpanze
rank
accord
increas
attenu
sever
promis
candid
vaccin
enter
clinic
trial
rsv
coldpassag
viru
two
addit
attenu
point
mutat
promis
vaccin
candid
test
far
still
caus
transient
nasal
stuffi
infant
wright
et
al
develop
revers
genet
system
rsv
provid
method
expedit
develop
attenu
virus
first
step
biolog
deriv
mutant
virus
sequenc
complet
mutat
identifi
evalu
introduct
individu
combin
wt
recombin
r
rsv
direct
identif
attenu
mutat
made
possibl
exampl
improv
mention
mutat
incorpor
one
addit
attenu
mutat
vaccin
candid
furthermor
mani
case
amino
acid
substitut
engin
involv
two
nucleotid
substitut
rel
wt
confer
increas
genet
stabil
similarli
revers
genet
system
establish
use
analyz
mutat
biolog
deriv
cold
passag
skiadopoulo
et
al
howev
capabl
revers
genet
go
far
beyond
analysi
exist
biolog
mutant
whole
new
set
method
gener
attenu
paramyxovirus
develop
describ
gene
knockout
mutat
ie
delet
nonessenti
gene
rsv
sh
g
gene
gener
number
vaccin
candid
differ
level
attenu
anoth
exampl
case
attenu
point
mutat
found
involv
residu
conserv
exampl
l
protein
rsv
c
protein
sendai
viru
transfer
attenu
mutat
heterolog
paramyxovirus
result
transfer
attenu
phenotyp
host
rang
restrict
could
employ
basi
attenu
creat
antigen
chimer
virus
use
anim
viru
platform
express
human
rsv
piv
glycoprotein
protect
antigen
gene
schmidt
et
al
manner
vaccin
candid
gener
replac
f
hn
glycoprotein
gene
counterpart
schmidt
et
al
thu
menu
avail
attenu
mutat
rsv
includ
numer
attenu
point
mutat
case
specifi
temperatur
sensit
case
gene
delet
host
rang
restrict
element
attenu
mutat
element
menu
combin
desir
develop
appropri
attenu
vaccin
candid
revers
genet
also
expedit
vaccin
develop
attenu
platform
use
make
vaccin
addit
virus
exampl
attenu
deriv
rsv
subgroup
use
gener
rsv
subgroup
b
vaccin
candid
replac
f
g
glycoprotein
gene
counterpart
strain
subgroup
b
whitehead
et
al
anoth
exampl
liveattenu
vaccin
candid
develop
replac
f
hn
code
region
counterpart
result
viru
thu
bear
antigen
determin
wt
backbon
attenu
introduct
mutat
attenu
menu
revers
genet
potenti
help
us
make
vaccin
satisfactorili
attenu
immunogen
wt
viru
protect
antigen
gene
move
closer
genom
promot
codon
usag
optim
translat
mammalian
host
cytokin
andor
chemokin
coexpress
addit
gene
bukreyev
et
al
reactogen
potenti
reduc
exampl
ablat
secret
form
rsv
g
might
decoy
antibodi
might
also
perturb
helper
lymphocyt
respons
vaccin
specif
broaden
ad
addit
gene
exist
vaccin
virus
eg
measl
hemagglutinin
ha
gene
express
addit
orf
gener
vaccin
candid
protect
measl
durbin
et
al
use
recombin
vaccin
vector
sever
advantag
exist
vector
system
reduc
number
virus
administr
infant
enabl
intranas
administr
therebi
mitig
neutral
immun
suppress
matern
antibodi
erad
measl
could
facilit
vaccin
includ
infecti
measl
viru
might
caus
prolong
infect
immunocompromis
host
summari
vaccin
optim
revers
genet
number
way
creation
novel
combin
mutat
finetun
attenu
phenotyp
provis
common
attenu
platform
gener
multival
vaccin
anim
model
rsv
rsv
initi
isol
chimpanze
develop
common
coldlik
diseas
sinc
chimpanze
anim
model
rsv
diseas
studi
extens
princip
higher
primat
use
three
differ
purpos
develop
live
viru
vaccin
recoveri
rsv
antibodi
lastli
evalu
formalininactiv
subunit
vaccin
studi
enhanc
diseas
follow
vaccin
formalininactiv
vaccin
number
anim
model
use
studi
rsv
diseas
among
ape
chimpanze
use
extens
sever
reason
permiss
rsv
core
bodi
temperatur
similar
human
symptomat
score
uri
possibl
rhinorrhea
score
permiss
chimpanze
make
possibl
perform
quantit
virolog
studi
upper
lower
respiratori
tract
time
cours
acut
rsv
infect
also
restrict
rsv
replic
respiratori
tract
chimpanze
correl
well
attenu
seroneg
human
infant
addit
human
immunolog
reagent
use
chimpanze
studi
howev
young
care
rais
chimpanze
rsv
seroneg
primat
use
includ
old
world
monkey
african
green
rhesu
cynomolog
bonnet
monkey
new
world
monkey
marmoset
tamarin
owl
monkey
although
monkey
semipermiss
rsv
core
bodi
temperatur
higher
human
level
attenu
temperaturesensit
rsv
mutant
might
overestim
although
primat
studi
provid
essenti
data
vaccin
develop
use
difficult
transport
care
primat
well
sampl
collect
difficult
potenti
danger
requir
welltrain
personnel
primat
research
center
must
provid
environ
similar
childcar
facil
therefor
mainten
cost
high
lamb
calv
also
use
studi
rsv
infect
mostli
ovin
bovin
rsv
caus
signific
diseas
natur
host
also
virus
import
econom
cotton
rat
mice
rodent
use
small
anim
model
mice
advantag
bodi
temperatur
similar
human
immunolog
reagent
readili
avail
also
gene
knockout
mice
transgen
mice
variou
inbr
strain
avail
studi
pathogenesi
mous
model
without
difficulti
howev
mice
acquir
larg
portion
matern
antibodi
suckl
therefor
optim
model
studi
immunosuppress
matern
antibodi
peak
rsv
titer
vari
among
differ
mous
strain
subgroup
b
rsv
poorli
infecti
immunogen
mice
immun
mechan
may
also
vari
among
differ
mice
strain
rodent
model
use
studi
quantit
virolog
immunolog
airway
pathophysiolog
model
wheez
weight
loss
use
surrog
marker
rsv
diseas
whichev
anim
model
one
choos
studi
respiratori
syncyti
viru
essenti
clearli
defin
whether
ultim
goal
studi
prepar
clinic
vaccin
trial
understand
basic
mechan
diseas
sever
coldpassag
cp
live
attenu
rsv
candid
vaccin
evalu
clinic
trial
candid
vaccin
deriv
attenu
origin
cprsv
chemic
mutagenesi
select
ts
mutant
first
two
vaccin
evalu
cpt
lineag
either
insuffici
attenu
transmit
amongst
seroneg
children
karron
et
al
studi
attenu
vaccin
candid
recent
complet
wright
et
al
viru
initi
evalu
chimpanze
replic
peak
titer
pfuml
upper
respiratori
tract
due
restrict
respiratori
tract
subsequ
evalu
clinic
studi
replic
adult
older
children
seroneg
children
month
age
howev
replic
peak
titer
pfuml
upper
respiratori
tract
induc
antibodi
respons
rsv
f
g
glycoprotein
viru
well
toler
age
group
frequenc
upper
lower
respiratori
tract
diseas
otiti
media
fever
differ
placebo
group
base
data
select
first
rsv
vaccin
administ
infant
repres
primari
target
group
vaccin
youngest
age
group
vaccin
recipi
develop
clinic
syndrom
character
nasal
congest
occur
typic
day
last
approxim
h
sinc
young
infant
oblig
nose
breather
interf
feed
caus
fussi
difficulti
fall
asleep
vaccin
recipi
shed
approxim
pfu
rsv
per
ml
nasal
wash
age
infant
level
matern
antibodi
rsv
affect
viru
shed
indic
viru
replic
nasopharynx
independ
variabl
young
infant
neutral
antibodi
respons
igg
elisa
respons
rsv
f
g
rare
detect
like
respons
mask
presenc
matern
deriv
antibodi
young
infant
howev
develop
serum
mucos
iga
respons
preferenti
rsv
g
glycoprotein
detect
serum
iga
correl
protect
reinfect
second
dose
vaccin
although
accept
vaccin
one
two
monthold
infant
sever
lesson
learn
studi
vaccin
candid
first
seroneg
infant
much
suscept
host
rsv
chimpanze
mean
attenu
vaccin
candid
chimpanze
model
rsv
infect
use
second
virus
replic
adult
older
children
attenu
enough
vaccin
infant
third
revers
genet
need
attenu
exist
biolog
rsv
vaccin
candid
two
recombin
rsv
vaccin
candid
current
evalu
clinic
trial
gener
delet
sh
gene
recombin
viru
engin
contain
addit
mutat
polymeras
protein
preliminari
data
suggest
recombin
virus
well
toler
children
associ
lower
respiratori
tract
ill
wherea
replic
well
parent
biolog
viru
without
sh
gene
delet
mutant
appear
much
restrict
replic
nasopharynx
restrict
induc
neutral
elisa
igg
antibodi
age
group
howev
sinc
viru
replic
well
like
suitabl
vaccin
one
two
month
old
infant
sh
current
evalu
one
two
month
old
infant
summari
although
close
ideal
vaccin
candid
modif
viru
revers
genet
addit
mutat
like
need
gener
rsv
vaccin
immunogen
yet
attenu
enough
given
young
infant
antibodi
prepar
neutral
free
viru
use
passiv
immunoprophylaxi
prevent
number
viral
diseas
includ
hepat
b
varicella
respiratori
syncyti
viru
rsv
diseas
efficaci
antibodi
prepar
prevent
rsv
diseas
establish
first
cotton
rat
chimpanze
model
later
extend
clinic
trial
therapi
rsv
infect
rsv
antibodi
howev
far
fail
prove
efficaci
malley
et
al
van
woensel
kimpen
import
mechan
action
antibodi
prepar
probabl
neutral
free
viru
occur
via
aggreg
free
viru
bival
multival
antibodi
via
receptor
blockad
via
antibodycompl
lysi
via
fusion
inhibit
receptor
blockad
thought
result
steric
inhibit
receptor
bind
rather
bind
antibodi
directli
receptorbind
site
even
receptor
bind
occur
viru
infect
neutral
fusion
inhibit
rsv
neutral
antibodi
thought
use
mechan
action
although
complet
antibodi
effect
neutral
free
viru
antibodi
bind
fragment
fab
alon
also
neutral
minim
unit
necessari
ablat
infect
probabl
peptid
correspond
one
loop
complementaritydetermin
region
although
neutral
nonneutr
antibodi
infecti
viru
often
distinguish
clear
whether
realli
antibodi
bind
glycoprotein
virion
without
neutral
virion
sakurai
et
al
mani
socal
nonneutr
antibodi
bind
purifi
conform
relax
rsv
f
glycoprotein
conform
correct
f
protein
infect
cell
differ
immunoglobulin
subclass
neutral
viru
vari
efficaci
mous
human
igg
subclass
also
bind
complement
vari
efficaci
replic
sendai
viru
murin
influenza
viru
inhibit
intracellularli
iga
similar
effect
iga
rsv
replic
may
occur
last
essenti
determin
neutral
activ
defin
amount
antibodi
avail
neutral
viru
prevent
rsv
diseas
lower
respiratori
tract
serum
neutral
antibodi
titer
approxim
requir
groothui
et
al
top
et
al
upper
respiratori
tract
infect
howev
prevent
serum
antibodi
titer
high
titer
achiev
experiment
set
small
rodent
model
singl
monoclon
antibodi
direct
rsv
g
protein
neutral
complet
cooper
neutral
occur
multipl
mab
use
effect
treatment
rsv
ill
limit
corticosteroid
bronchodil
ribavirin
recent
rsv
mab
use
none
therapeut
intervent
accept
reproduc
efficaci
seem
neither
antivir
antiinflammatori
agent
alon
improv
outcom
rsv
diseas
singl
dose
topic
administ
human
fab
shown
clear
free
viru
respiratori
tract
rodent
effect
shortliv
sinc
infect
cell
releas
newli
synthes
infecti
viru
within
day
two
crow
et
al
wherea
peak
viru
titer
human
usual
occur
around
day
patient
clinic
rsv
diseas
like
present
earlier
day
point
viru
load
alreadi
declin
may
late
antivir
antiinflammatori
drug
map
kinas
inhibitor
may
effect
reduc
cell
injuri
immunolog
consequ
passiv
immunoprophylaxi
chimpanze
therapi
rsv
antibodi
suppress
primari
antibodi
respons
rsv
effect
mostli
antigenspecif
may
also
nonspecif
aspect
mediat
fc
portion
antibodi
secondari
antibodi
respons
rsv
chimpanze
enhanc
prior
antibodi
therapi
howev
effect
observ
mice
clinic
studi
cell
respons
seem
affect
antibodi
therapi
humor
respons
cell
might
fill
absent
primari
antibodi
respons
whether
desir
effect
remain
uncertain
without
safe
effect
rsv
vaccin
avail
monthli
infus
rsvigiv
respigam
first
effect
measur
prevent
rsvinduc
lower
respiratori
tract
infect
lri
hospit
infant
evalu
rsvivig
cotton
rat
correctli
predict
serum
concentr
necessari
protect
rsvinduc
lri
princ
et
al
protect
concentr
children
achiev
monthli
infus
mgkg
rsvivig
order
increas
potenc
rsv
antibodi
prepar
order
abl
replac
intraven
intramuscular
administr
human
monoclon
antirsv
fusion
protein
antibodi
develop
mous
monoclon
antibodi
develop
laboratori
infecti
diseas
nih
rsv
f
protein
antigen
site
one
two
antigen
site
conserv
amongst
differ
rsv
strain
select
human
base
vitro
vivo
studi
complementar
determin
region
cdr
transfer
mous
antibodi
human
igg
human
igg
pharmacokinet
similar
human
igg
permit
repeat
administr
monthli
interv
chosen
mab
crossreact
adult
neonat
tissu
broadli
neutral
rsv
subgroup
subgroup
b
isol
concentr
ngml
prove
time
activ
weight
basi
rsvivig
cotton
rat
model
johnson
et
al
adult
volunt
toler
dose
human
antibodi
mgkg
well
volunt
develop
lowtit
transient
antiidiotyp
antibodi
respons
halflif
day
expect
igg
serum
concentr
iv
im
administr
compar
except
initi
bioavail
safe
well
toler
phase
iii
studi
highrisk
children
specif
immunogen
monthli
dosag
mgkg
maintain
serum
concentr
greater
mgml
singl
intraven
dose
mgkg
reduc
rsv
titer
tracheal
secret
intub
children
rsv
infect
malley
et
al
impactrsv
studi
led
fda
approv
also
call
palivizumab
random
doubleblind
placebocontrol
phase
iii
multicent
studi
conduct
site
us
canada
uk
studi
subject
receiv
five
dose
placebo
interv
day
follow
total
day
primari
endpoint
studi
overal
rsvrelat
hospit
significantli
reduc
pb
placebo
recipi
n
recipi
prematur
infant
chronic
lung
diseas
incid
rsv
hospit
reduc
p
prematur
infant
without
chronic
lung
diseas
reduc
pb
total
rsv
hospit
day
total
day
increas
oxygen
requir
total
day
sever
lri
rate
icu
admiss
total
day
icu
secondari
endpoint
occur
less
frequent
treat
group
p
b
thu
administr
mgkg
im
inject
found
safe
welltoler
lead
reduct
rsv
hospit
highrisk
children
group
conclus
confirm
outcom
survey
conduct
nine
center
highrisk
children
receiv
mgkg
palivizumab
although
direct
comparison
impactrsv
studi
possibl
rsv
hospit
rate
low
similar
observ
impactrsv
studi
vs
impactrsv
studi
prematur
infant
without
cld
vs
children
cld
hospit
rsv
season
sorrentino
power
altern
strategi
protect
neonat
young
infant
sever
rsv
diseas
vaccin
pregnant
women
transfer
high
concentr
matern
rsvspecif
igg
fetu
expect
protect
infant
sever
diseas
glezen
et
al
safeti
immunogen
respiratori
syncyti
viru
purifi
fusion
wyeth
lederl
vaccin
pediatr
pearl
river
ny
recent
evalu
use
pregnanc
thirtyf
pregnant
women
random
ratio
receiv
rsv
salin
placebo
week
gestat
follow
time
deliveri
infant
follow
first
year
life
first
rsv
season
rsv
safe
well
toler
pregnant
women
system
reaction
seriou
advers
event
associ
vaccin
administr
infant
born
healthi
differ
frequenc
outcom
neonat
event
group
first
rsv
season
increas
frequenc
sever
respiratori
tract
ill
infant
vaccin
recipi
ampl
materi
draw
lesson
relev
need
prepar
pandem
influenza
date
respons
specif
prepar
deal
seriou
pandem
influenza
remain
realm
academ
reflect
meaning
action
although
much
time
devot
develop
nation
respons
plan
seem
much
better
equip
deal
new
pandem
influenza
spring
strain
influenza
viru
emerg
time
face
burgeon
epidem
whose
virul
propens
spread
yet
unknown
program
surveil
field
epidemiolog
better
defin
epidem
develop
time
prepar
need
distribut
use
new
influenza
vaccin
arriv
time
appear
today
much
progress
made
past
year
still
real
sens
urgenc
deal
essenti
problem
felt
although
much
written
epidem
still
perceiv
interest
question
relev
tale
death
diseas
earlier
preantibiot
era
medicin
mani
doubt
epidem
sever
would
possibl
today
fact
first
import
recogn
us
dwarf
outbreak
centuri
time
million
die
worldwid
unit
state
regist
death
variou
studi
thought
overal
perhap
popul
becam
ill
die
medic
servic
overwhelm
support
care
littl
cur
medicin
could
offer
death
numer
burial
greatli
delay
lack
mortician
grave
digger
pictur
time
provid
least
pale
illumin
catastroph
period
effect
diseas
anyth
uniform
survey
reveal
morbid
rate
rang
differ
part
countri
remot
rural
area
escap
diseas
entir
area
remark
lethal
western
samoa
new
zealand
protector
regist
death
popul
repres
entir
popul
curious
american
samoa
mile
away
quarantin
effect
one
polit
entiti
escap
epidem
entir
surpris
uniqu
epidem
half
death
person
year
age
age
bracket
death
rel
uncommon
phenomenon
pregnant
women
cardiac
problem
highest
risk
die
otherwis
good
health
substanti
number
age
group
die
fulmin
rapidli
progress
pneumonia
mark
sever
cyanosi
death
occur
within
matter
day
brief
seem
almost
certainli
primari
influenza
pneumonia
would
benefit
littl
antibiot
avail
today
better
outcom
might
foreseen
better
ventilatori
support
intens
care
unit
administr
antivir
agent
administr
antibiot
treatment
secondari
pulmonari
infect
epidem
circumst
bulk
case
new
pandem
would
occur
period
week
fraction
patient
could
accommod
suitabl
hospit
set
let
alon
appropri
intens
care
unit
quantiti
antivir
drug
avail
emerg
use
obtain
ad
quantiti
standard
antibiot
today
produc
justintim
basi
period
clinic
facil
stress
regularli
experienc
antibiot
shortag
regular
rotat
basi
cogent
question
whether
epidem
circumst
modern
health
care
system
could
provid
standard
clinic
care
would
better
still
anoth
dimens
problem
appreci
pandem
characterist
emerg
new
influenza
strain
mean
exactli
worldwid
epidem
mani
countri
develop
develop
made
prepar
inevit
turn
resourc
help
deal
catastroph
catastroph
pose
intern
secur
threat
rapid
product
administr
larg
volum
vaccin
effect
emerg
new
strain
basic
build
block
strategi
deal
pandem
influenza
understand
given
limit
cur
medicin
capac
clinic
servic
first
real
test
strategi
came
epidem
first
notic
major
outbreak
occur
mid
april
specimen
receiv
us
may
field
test
new
lot
vaccin
began
juli
bad
record
foreseen
million
dose
would
requir
good
fortun
adapt
viru
grow
reason
high
titer
egg
membran
provid
suffici
fertil
egg
could
obtain
expect
product
target
februari
could
met
even
problemat
date
given
season
peak
epidem
influenza
usual
occur
end
decemb
end
februari
still
believ
substanti
number
would
abl
protect
howev
typic
year
one
must
note
case
epidem
strain
first
appear
widespread
epidem
began
occur
mid
late
septemb
two
month
anticip
half
counti
report
epidem
midoctob
end
octob
peak
incid
past
long
substanti
quantiti
vaccin
avail
given
experi
could
expect
anoth
new
strain
behav
differ
today
past
year
extens
studi
conduct
search
satisfactori
live
attenu
vaccin
variou
approach
product
would
permit
new
antigen
variant
produc
rapidli
quantiti
tissu
cell
cultur
howev
today
still
produc
influenza
vaccin
allanto
caviti
hen
egg
procur
adequ
suppli
fertil
egg
time
manner
remain
seriou
problem
difficulti
adapt
new
strain
egg
remain
abl
solv
vaccin
product
problem
countri
would
end
practic
quandari
deal
pandem
countri
influenza
vaccin
product
capabl
intern
implic
us
much
vaccin
suppli
profound
follow
swine
influenza
outbreak
fort
dix
new
jersey
us
embark
program
rapidli
produc
appropri
vaccin
vaccin
product
capabl
europ
countri
margin
world
health
organ
committe
could
recommend
fort
dix
situat
care
monitor
strategi
wait
hope
meet
comment
corridor
convers
would
wish
face
ethic
polit
dilemma
unit
state
would
face
pandem
us
nation
vaccin
recent
meet
nation
local
hospit
author
current
capabl
medic
system
us
deal
sudden
surg
demand
might
follow
releas
biolog
weapon
explor
releas
would
result
epidem
would
stress
system
unlik
way
would
stress
pandem
sever
influenza
meet
evid
elast
nation
bed
suppli
significantli
reduc
drive
financi
effici
increas
use
outpati
procedur
sharpli
reduc
number
bed
hospit
meanwhil
manag
caredriven
market
pressur
feder
govern
reimburs
reduct
driven
larg
number
hospit
oper
deficit
mani
municip
hospit
primari
sourc
care
less
prosper
uninsur
privat
meanwhil
hospit
experienc
sever
labor
shortag
especi
nurs
technic
personnel
either
resourc
motiv
prepar
respond
challeng
pose
mass
casualti
due
caus
reserv
antibiot
note
earlier
margin
nil
public
health
infrastructur
need
deal
epidem
diseas
grossli
understaf
underpaid
train
mechan
develop
implement
communitywid
plan
larg
unexplor
unreason
suggest
today
less
wellprepar
deal
epidem
influenza
year
ago
paramet
one
identifi
might
new
strain
influenza
mean
term
number
case
death
estim
past
pandem
suggest
perhap
popul
affect
first
wave
rise
proport
popul
urban
area
greater
rapid
mix
popul
travel
figur
less
would
seem
reason
thu
citi
million
one
might
expect
million
case
influenza
doubt
either
antibiot
antivir
agent
would
much
help
given
number
case
dearth
reserv
suppli
number
death
would
vari
greatli
depend
strain
hong
kong
recent
new
strain
result
death
among
six
person
infect
spread
readili
howev
estim
strain
kill
becam
ill
casefat
rate
onetenth
larg
thu
citi
million
person
one
might
anticip
death
period
week
medic
care
would
consist
larg
support
therapi
given
number
ill
public
health
measur
likewis
would
consist
littl
reassur
given
likelihood
vaccin
suppli
would
avail
stock
antivir
drug
would
small
signific
mani
would
argu
close
school
church
place
public
gather
experi
suggest
action
produc
littl
benefit
wear
mask
favor
intervent
discredit
brief
without
vaccin
would
littl
could
done
practic
benefit
except
reassur
commun
epidem
would
someday
pass
accept
critic
public
polit
leadership
failur
make
reason
prepar
least
four
lesson
deriv
past
experi
first
threat
pandem
influenza
caus
especi
virul
strain
continu
threat
taken
serious
second
adequ
suppli
effect
vaccin
avail
time
manner
absolut
critic
prevent
effort
solv
problem
command
top
prioriti
research
develop
fund
third
special
plan
program
fund
need
within
health
care
system
permit
develop
adequ
communitywid
respons
occurr
mass
casualti
whatev
caus
lastli
addit
research
influenza
need
better
understand
pathogenesi
epidemiolog
expect
better
prevent
measur
might
eventu
pandem
dramat
present
influenza
viru
caus
consider
excess
mortal
result
pneumonia
exacerb
cardiopulmonari
chronic
diseas
epidemiolog
success
influenza
larg
part
due
antigen
variat
take
place
two
surfac
glycoprotein
viru
ie
hemagglutinin
ha
neuraminidas
na
protein
date
ha
na
subtyp
defin
use
classifi
influenza
virus
antigen
variat
occur
either
gradual
accumul
point
mutat
antigen
drift
abruptli
though
introduct
new
ha
gene
viru
circul
human
popul
reassort
anim
human
virus
chang
hostspecif
anim
viru
antigen
shift
pandem
viru
defin
viru
new
ha
without
novel
na
gene
acquir
antigen
shift
spread
readili
persontoperson
popul
highli
suscept
infect
centuri
saw
three
pandem
caus
new
ha
subtyp
influenza
caus
spanish
flu
subtyp
asian
flu
caus
agent
pandem
subtyp
hong
kong
flu
caus
pandem
excess
mortal
pandem
us
alon
estim
death
respect
one
appli
mathemat
model
estim
effect
futur
pandem
us
alon
expect
excess
death
next
pandem
meltzer
et
al
virus
pandem
potenti
individu
hong
kong
infect
influenza
avian
subtyp
earlier
known
infect
human
subbarao
et
al
patient
year
age
six
die
molecular
analysi
establish
eight
gene
viru
avian
origin
reassort
human
virus
occur
subbarao
et
al
report
infect
like
acquir
poultri
humantohuman
spread
howev
rare
event
sequenc
analysi
hong
kong
viru
suggest
reassort
made
two
three
differ
avian
parent
virus
ha
goos
viru
xu
et
al
na
teal
viru
hoffmann
et
al
intern
gene
quail
guan
et
al
teal
viru
hoffmann
et
al
although
viru
spread
readili
person
person
deep
concern
caus
fact
first
known
avian
influenza
viru
caus
diseas
human
outbreak
thought
receptor
specif
avian
ha
protein
limit
infect
avian
speci
notion
howev
need
revis
march
influenza
virus
isol
two
children
febril
upper
respiratori
tract
ill
peiri
et
al
viru
avian
viru
abl
infect
human
without
passag
intermedi
host
lin
et
al
option
vaccin
potenti
pandem
virus
case
virus
four
option
gener
effect
influenza
vaccin
convent
inactiv
vaccin
theoret
gener
reassort
intern
gene
influenza
glycoprotein
gene
howev
problem
incompat
certain
gene
segment
secondli
cold
adapt
live
attenu
vaccin
approach
could
taken
influenza
aann
coldadapt
strain
use
gener
vaccin
ha
cleavag
site
modifi
li
et
al
viru
could
also
use
produc
inactiv
vaccin
thirdli
surrog
viru
nonpathogen
antigen
relat
takada
et
al
could
sought
one
closest
antigen
relat
virus
found
date
subtyp
viru
highli
immunogen
human
fourthli
purifi
protein
could
use
limit
immunogen
may
problem
develop
vaccin
potenti
pandem
virus
pose
number
challeng
begin
work
conduct
biosafeti
level
laboratori
larg
array
avian
virus
could
potenti
becom
pandem
virus
genotyp
confer
transmiss
identifi
virus
genet
precursor
virus
caus
human
infect
hong
kong
guan
et
al
xu
et
al
hoffmann
et
al
continu
circul
among
bird
certainli
given
prioriti
vaccin
develop
adequ
strategi
vaccin
develop
select
safeti
test
must
expedit
mice
ferret
chicken
eventu
human
use
recent
describ
plasmid
base
revers
genet
system
may
lessen
technic
challeng
face
gener
vaccin
candid
assay
evalu
immun
optim
hemagglutin
inhibit
assay
perform
well
avian
ha
protein
yet
neutral
assay
time
consum
technic
difficult
serolog
molecular
diagnost
reagent
must
made
avail
collabor
veterinari
public
health
author
must
maintain
new
technolog
plasmid
base
revers
genet
system
must
use
last
least
altern
substrat
vaccin
product
new
adjuv
urgent
need
although
influenza
epidem
occur
everi
winter
three
pandem
past
centuri
annual
influenza
epidem
gener
caus
excess
mortal
peopl
us
pandem
remain
memori
three
pandem
occur
twentieth
centuri
pandem
devast
claim
victim
although
wide
spread
public
interest
pandem
event
mostli
rememb
interest
event
distant
past
whether
due
denial
feel
influenza
pandem
current
threat
journalist
see
role
educ
advoc
also
entertain
interest
readership
captur
maintain
curios
satisfi
aid
pandem
effect
peopl
live
found
wide
audienc
earli
late
character
fatigu
reduc
interest
pandem
although
still
increas
result
editor
much
less
will
includ
relat
stori
reportag
influenza
pandem
suffer
similar
fate
diseas
old
last
pandem
occur
long
ago
rememb
mere
warn
come
pandem
almost
perceiv
unfulfil
promis
event
occur
shortli
articl
publish
breast
cancer
contrast
one
exampl
interest
diseas
process
maintain
extend
period
time
risk
suffer
breast
cancer
felt
much
acut
seem
sens
proactiv
behavior
lead
improv
outcom
whether
mass
media
take
role
chang
public
attitud
toward
influenza
threat
much
doubt
long
journalist
perceiv
next
pandem
event
anonym
inevit
earthquak
rsv
infect
initi
g
glycoprotein
attach
cell
surfac
receptor
follow
viruscel
fusion
mediat
f
protein
cleavageactiv
rsv
protein
thought
interact
target
cell
membran
ntermin
fusion
peptid
releas
shield
posit
within
f
homotrim
major
conform
chang
insert
nterminu
cell
membran
destabil
cell
membran
induc
lipid
mix
follow
mix
content
therebi
enabl
viral
nucleocapsid
enter
cytoplasm
rsv
f
protein
recent
found
interact
small
gtpase
call
rhoa
domain
lie
carboxytermin
fusion
peptid
pastey
et
al
rhoa
member
ra
superfamili
express
intracellularli
cell
type
induc
bundl
actin
filament
stress
fiber
focal
adhes
plaqu
format
celltocel
adhes
organ
integr
membran
protein
addit
role
cell
morpholog
motil
well
cell
cycl
transit
seri
overlap
rhoa
peptid
interact
domain
evalu
rsv
plaqu
reduct
neutral
assay
rhoa
peptid
ic
mgml
inoculum
pfu
neutral
activ
also
seen
parainfluenza
viru
type
varieti
paramyxo
orthmyxo
corona
filovirus
pastey
et
al
intranas
administr
mg
peptid
prior
intranas
infect
mice
rsv
reduc
rsv
replic
also
diminish
weightloss
studi
recombin
rsv
express
green
fluoresc
protein
indic
rhoa
peptid
inhibit
rsv
replic
earli
stage
infect
subsequ
shown
fusion
cell
transfect
rsv
f
g
sh
inhibit
peptid
suggest
exert
effect
rsv
replic
level
membran
fusion
entri
sinc
rhoa
intracellular
molecul
one
would
hypothes
interact
ntermin
heptad
repeat
fusion
peptid
target
membran
caus
enough
membran
disrupt
allow
interact
rhoa
rsv
f
altern
rsv
f
may
interact
rhoa
entri
process
rhoaderiv
peptid
may
simpli
disrupt
f
structur
function
render
viru
noninfecti
question
whether
rhoa
rsv
f
interact
natur
infect
yet
resolv
rhoa
found
cytoplasm
bound
gdp
guanin
nucleotid
dissoci
inhibitor
upon
gtp
exchang
isoprenyl
rhoa
associ
cell
membran
propos
model
rhoarsv
f
interact
membran
correct
inhibit
isoprenyl
inhibit
rsv
infect
inde
inhibit
isoprenyl
hmg
coa
reductas
inhibitor
lovastatin
inhibit
rsv
infect
cell
ic
mm
reduc
peak
rsv
titer
lung
mice
greater
oral
gavag
mg
per
day
gower
tl
graham
bs
submit
antivir
effect
lovastatin
also
seen
vitro
although
formal
proven
rsv
f
interact
rhoa
infect
cell
membran
rhoa
signal
activ
trigger
rsvinfect
cell
gower
tl
et
al
submit
rhoa
signal
requir
rsv
replic
syncytium
format
diminish
rhoa
signal
activ
inhibit
addit
rhoa
signal
may
play
role
aspect
rsv
pathogenesi
rhoa
kinas
inhibitor
reduc
transcript
mrna
rsv
infect
cell
cytokin
abund
nasal
secret
rsvinfect
patient
obviat
airway
hyperrespons
one
cardin
symptom
rsv
diseas
hashimoto
k
et
al
submit
balbc
mous
model
use
explor
whether
mycophenol
acid
mpa
inhibitor
de
novo
purin
synthesi
b
lymphocyt
could
improv
outcom
rsv
diseas
monitor
clinic
symptom
ruffl
fur
increas
respiratori
rate
weight
loss
oral
administr
mgkg
mmf
prodrug
mpa
daili
day
postinfect
reduc
weight
loss
day
postinfect
untreat
anim
mpa
treat
mice
p
b
reduct
weight
loss
also
observ
initi
treatment
delay
day
postinfect
viru
titer
lung
mmf
treat
mice
similar
untreat
control
histolog
chang
reduc
day
postinfect
ifng
level
elev
treatment
group
level
unchang
indic
shift
toward
helper
cell
type
respons
thought
correl
improv
rsv
diseas
outcom
data
suggest
inflammatori
respons
contribut
rsv
diseas
mice
immunomodulatori
approach
treatment
human
rs
viru
diseas
worth
consider
use
cellbas
assay
identifi
compound
abl
inhibit
fusion
hela
cell
infect
rsv
analogu
lead
compound
synthes
one
compound
term
select
evalu
vitro
inhibitori
concentr
ic
benzimidazol
deriv
mw
pm
thu
potenc
exce
ribavirin
almost
ic
mm
exhibit
vitro
antivir
activ
human
rsv
subgroup
b
bovin
rsv
pneumoviru
mice
paramyxovirus
rsvinduc
cytopath
effect
reduc
nm
concentr
nm
reduc
rsv
titer
multicycl
growth
curv
time
addit
studi
indic
viruscel
fusion
cellcel
fusion
inhibit
compound
select
resist
virus
vitro
yield
two
mutant
singl
point
mutat
fprotein
one
upstream
second
heptad
repeat
motif
anoth
within
rsv
titer
determin
quantit
rtpcr
reduc
bronchoalveolar
lavag
fluid
lung
tissu
cotton
rat
treat
inhal
prior
rsv
infect
compound
deriv
chemic
optim
earlier
describ
antivir
small
molecul
antivir
drug
select
inhibit
rsv
wyde
et
al
molecul
watersolubl
oral
bioavail
prove
efficaci
administ
intranas
inhal
vitro
ic
vari
ngml
laboratori
strain
clinic
isol
rsv
subgroup
b
viral
specif
larg
therapeut
window
fold
indic
antivir
activ
compound
due
advers
effect
normal
cell
addit
cell
cultur
prior
adsorpt
reduc
rsv
yield
h
post
infect
wyde
et
al
temperatur
shift
experi
suggest
rsv
f
protein
target
observ
confirm
inhibitori
effect
rsv
viabl
rsv
mutant
g
sh
open
read
frame
delet
ad
cell
cultur
h
post
infect
inhibit
syncytium
format
indic
fusion
inhibit
occur
earli
late
phase
infecti
cycl
virus
select
albeit
much
less
easili
amantadin
resist
variant
resist
acquir
point
mutat
sole
f
protein
mostli
upstream
second
heptad
repeat
motif
mutat
g
sh
protein
administ
prophylact
intranas
rout
inhibit
rsv
replic
vivo
mice
cotton
rat
exhibit
reduct
rsv
replic
day
post
infect
african
green
monkey
reduc
peak
rsv
titer
administ
prophylact
also
therapi
initi
h
post
infect
continu
total
day
nebul
form
shown
activ
monkey
preclin
profil
drug
support
develop
treatment
prophylaxi
rsv
diseas
pediatr
adult
geriatr
popul
phase
clinic
trial
confirm
potent
antivir
safeti
profil
drug
encourag
proteas
inhibitor
potent
irrevers
inhibitor
human
rhinoviru
hrv
proteas
enzym
respons
cleavag
viral
polyprotein
function
protein
subunit
matthew
et
al
discov
protein
structur
base
ration
drug
design
compound
exhibit
activ
larg
set
differ
hrv
effect
concentr
ec
rang
mm
piconavirus
coxsackieviru
enteroviru
echoviru
also
sensit
compound
placebo
control
challeng
studi
adult
volunt
infect
treat
mg
per
dose
intranas
time
per
day
reduc
mean
viral
titer
well
mucu
weight
respiratori
symptom
score
total
symptom
score
significantli
studi
viral
titer
determin
cultur
also
quantit
pcr
taqman
exclud
exvivo
effect
reduct
viru
titer
phase
ii
clinic
trial
subject
conduct
determin
efficaci
natur
acquir
piconaviru
infect
patient
select
studi
present
within
h
onset
symptom
suffer
least
two
mild
one
moder
cold
symptom
five
step
symptom
score
use
record
sever
rhinorrhea
cough
sneez
sore
throat
chill
headach
malais
treatment
group
stratifi
two
four
daili
dose
mg
per
dose
intranas
mean
respiratori
symptom
score
day
chosen
primari
endpoint
enrol
patient
infect
picornavirus
signific
differ
respiratori
total
mean
symptom
score
day
detect
howev
drug
well
toler
safe
lack
efficaci
particular
studi
might
due
lower
expect
frequenc
picornaviru
infect
retrospect
analysi
stratif
start
therapi
within
h
detect
trend
fewer
respiratori
symptom
fewer
total
symptom
trend
earlier
onset
relief
differ
treatment
placebo
group
reach
signific
pleconaril
p
treatment
reduc
incid
acut
otiti
media
om
children
respiratori
ill
pilot
studi
pleconaril
oral
bioavail
picornaviru
proteas
inhibitor
vitro
antivir
activ
rhinovirus
evalu
efficaci
pleconaril
prevent
acut
otiti
media
aom
outpati
popul
doubleblind
placebocontrol
pilot
studi
conduct
children
viral
respiratori
ill
eightyseven
children
median
age
year
histori
episod
aom
random
pleconaril
treatment
mgkg
mgkg
placebo
thrice
daili
day
follow
present
upper
respiratori
symptom
picornaviru
rna
detect
rtpcr
nasal
sampl
patient
baselin
overal
incid
physiciandiagnos
aom
day
followup
placebo
low
dose
high
dose
group
respect
children
develop
aom
test
posit
picornaviru
rna
pleconaril
treatment
reduc
frequenc
nasal
symptom
high
dose
mgkg
p
low
dose
mgkg
p
group
reduc
frequenc
system
symptom
mgkg
group
p
mgkg
group
p
pleconaril
well
toler
advers
event
differ
control
group
result
encourag
expand
trial
pleconaril
children
viral
respiratori
infect
oral
reduc
influenzarel
complic
age
group
influenza
ill
associ
develop
secondari
complic
often
requir
antibiot
treatment
even
hospit
insur
data
indic
influenza
relat
hospit
admiss
occur
year
old
individu
often
without
recogn
underli
disord
influenza
complic
affect
age
group
type
complic
differ
among
acut
otiti
media
report
children
influenza
lower
respiratori
tract
infect
lrti
bronchiti
less
often
pneumonia
common
complic
adult
recent
year
six
phase
iii
clinic
trial
complet
two
pediatr
popul
three
healthi
adult
one
elderli
neuraminidas
inhibitor
oseltamivir
alreadi
approv
treatment
influenza
adult
recent
approv
treatment
children
age
year
older
fda
six
phase
iii
trial
patient
enrol
within
h
onset
symptom
oseltamivir
administ
mgkg
twice
daili
children
mg
twice
daili
adult
subject
febril
influenza
random
day
regimen
oseltamivir
placebo
import
endpoint
studi
effect
oral
oseltamivir
incid
influenzarel
complic
requir
antibiot
one
thousand
twenti
nine
children
age
mean
age
year
enrol
pediatr
trial
adult
elderli
popul
patient
mean
age
year
elderli
patient
mean
age
year
enrol
pediatr
adult
elderli
trial
respect
test
posit
influenza
b
cultur
fourfold
increas
hai
titer
physiciandiagnos
secondari
complic
bronchiti
pneumonia
lrti
sinus
otiti
media
requir
antibiot
assess
patient
confirm
influenza
infect
oseltamivir
reduc
rate
complic
compar
placebo
children
p
adult
p
p
elderli
p
p
pediatr
popul
aom
common
complic
follow
bronchiti
pneumonia
sinus
frequenc
aom
reduc
placebo
group
oseltamivir
group
signific
reduct
adult
elderli
bronchiti
sinus
common
complic
influenza
frequenc
bronchiti
elderli
reduc
thu
oral
oseltamivir
reduc
incid
secondari
complic
associ
antibiot
use
age
group
age
group
combin
antibiot
use
indic
also
significantli
reduc
twelv
patient
placebo
group
versu
four
patient
oseltamivir
group
requir
hospit
probabl
possibl
influenzarel
complic
suggest
possibl
effect
hospit
neuraminidas
inhibitor
clinic
updat
oseltamivir
recent
approv
us
prophylaxi
influenza
adult
adolesc
year
age
three
success
phase
three
trial
one
conduct
healthi
adult
one
famili
set
infecti
index
case
anoth
evalu
season
prophylaxi
elderli
efficaci
oseltamivir
three
trial
rang
applic
approv
oseltamivir
treatment
influenza
children
one
year
age
recent
approv
fda
otherwis
healthi
children
year
treatment
oseltamivir
reduc
median
time
freedom
ill
day
p
b
also
reduc
rel
risk
otiti
media
aom
year
old
asthmat
children
oseltamivir
treatment
start
within
h
first
symptom
decreas
median
ill
durat
day
p
airway
function
significantli
improv
forc
expiratori
volum
day
improv
compar
baselin
valu
among
oseltamivir
recipi
among
placebo
recipi
p
incid
develop
drug
resist
viru
therapi
evalu
subject
none
subject
sampl
day
treatment
harbor
resist
viru
day
howev
subject
shed
viru
resist
phenotyp
children
frequenc
viral
resist
subject
recov
normal
despit
incident
find
far
resist
mutant
less
infecti
wild
type
viru
evid
transmiss
detect
experiment
infect
model
ferret
impact
studi
evalu
benefit
earli
intervent
reduc
total
time
symptom
start
time
first
onset
fever
reflect
total
burden
ill
patient
point
view
total
patient
year
age
enrol
treat
within
h
first
onset
symptom
treatment
initi
within
h
recruit
use
acceler
time
failur
model
earlier
intervent
shown
strongli
correl
shorter
durat
ill
total
durat
ill
could
halv
treatment
start
within
h
onset
symptom
compar
intervent
h
phase
iii
trial
zanamivir
reduc
durat
ill
adult
year
age
children
year
age
day
ci
day
high
risk
patient
subject
asthma
chronic
obstruct
pulmonari
diseas
durat
ill
amongst
influenza
posit
subject
reduc
day
durat
ill
reduc
vaccin
day
nonvaccin
day
subject
therapi
pulmonari
function
improv
slightli
day
zanamivir
well
toler
differ
advers
effect
treatment
placebo
group
subject
studi
clinic
trial
resist
mutant
isol
sampl
day
efficaci
treatment
influenza
b
assess
subject
found
similar
influenza
prophylaxi
studi
famili
set
show
protect
efficaci
final
nurs
home
studi
zanamivir
exhibit
increas
efficaci
prevent
influenza
diseas
compar
rimantadin
oral
avail
daili
neuraminidas
inhibitor
activ
influenza
b
vitro
anim
evalu
phase
ii
trial
experiment
infect
healthi
adult
therapi
start
approxim
h
post
infect
influenza
atexa
influenza
byamagata
viral
load
time
primari
endpoint
nasal
wash
titer
determin
everi
h
day
daili
thereaft
influenza
studi
subject
enrol
four
treatment
mg
per
day
one
placebo
arm
high
dose
treatment
mg
daili
mg
twice
daili
reduc
viral
load
wherea
mg
per
day
led
reduct
shed
reduc
day
high
dose
group
incid
fever
declin
placebo
control
less
treatment
group
combin
evalu
efficaci
influenza
b
subject
enrol
two
treatment
mg
per
day
one
placebo
group
reduct
viral
load
shown
high
dose
treatment
mg
per
day
evid
emerg
resist
viru
detect
oral
rwj
well
toler
without
excess
gastrointestin
side
effect
worldwid
acut
respiratori
infect
ari
respons
million
death
per
year
children
five
year
age
viral
respiratori
infect
contribut
significantli
burden
diseas
children
also
adult
although
myriad
viral
respiratori
pathogen
number
viru
famili
caus
signific
burden
diseas
limit
children
paramyxovirida
import
famili
virus
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
caus
diseas
follow
adenoand
influenza
virus
adult
influenza
viru
constantli
chang
antigen
composit
surpass
viral
pathogen
impact
rsv
rhinovirus
increasingli
appreci
epidemiolog
respiratori
viru
infect
much
depend
host
environment
factor
adenoviru
infect
major
concern
militari
train
camp
immunocompromis
patient
import
gener
adult
popul
immunocompromis
increas
risk
viral
respiratori
diseas
diagnosi
manag
much
difficult
group
newer
diagnost
method
base
antigen
detect
viral
genom
amplif
make
rapid
diagnosi
possibl
therebi
affect
clinic
manag
viral
respiratori
diseas
vaccin
still
power
tool
prevent
viral
respiratori
diseas
mani
import
pathogen
still
vaccin
avail
inactiv
influenza
vaccin
antigen
composit
chang
annual
still
mainstay
influenza
prevent
coldadapt
live
attenu
influenza
viru
vaccin
horizon
yet
approv
fda
adenoviru
vaccin
use
success
militari
mani
year
recent
resurg
larg
outbreak
respiratori
diseas
discontinu
vaccin
emphas
import
maintain
prevent
strategi
live
viru
vaccin
candid
rsv
piv
deriv
biolog
revers
genet
current
clinic
trial
hope
safe
effici
vaccin
becom
avail
within
decad
new
insight
virushost
virusbacteria
interact
viral
respiratori
ill
may
help
us
understand
complex
diseas
entiti
allow
reevalu
manag
option
diseas
earlier
thought
pure
bacteri
otiti
media
might
effect
prevent
viral
vaccin
bacteri
vaccin
popul
high
risk
complic
result
respiratori
viral
infect
better
defin
target
prophylaxi
possibl
passiv
prophylaxi
rsv
diseas
monoclon
antibodi
prepar
activ
prophylaxi
influenzaor
adenoviru
vaccin
manag
influenza
viru
diseas
much
chang
better
neuraminidas
inhibitor
ni
establish
effect
intervent
decreas
sever
shorten
durat
ill
therapi
initi
within
day
onset
symptom
zanamivir
oseltamivir
licens
us
elsewher
adult
adolesc
twelv
year
age
older
licens
use
children
one
year
age
recent
obtain
oseltamivir
drug
safe
well
toler
develop
resist
occur
much
less
frequent
older
antivir
amantadin
rimantadin
rhinoviru
infect
caus
cold
may
amen
treatment
experiment
proteas
inhibitor
pleconaril
given
oral
given
intranas
initi
studi
indic
pleconaril
treatment
cold
children
might
reduc
risk
develop
otiti
media
antivir
effect
rsv
piv
still
earli
phase
develop
inhibitor
viral
fusion
protein
look
promis
despit
progress
sever
defici
remain
prevent
effort
level
prepared
influenza
pandem
seem
much
differ
year
ago
streamlin
hospit
infrastructur
justintim
product
antibiot
antivir
limit
abil
respond
effect
pandem
strike
although
potenti
pandem
influenza
virus
defin
novel
techniqu
revers
genet
employ
vaccin
develop
implement
pandem
prepared
still
daunt
task
